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RESUME 
Mecanismes de la resistance intrinseque a l'apoptose induite par TRAIL chez les 
cellules de cancer ovarien 
par 
Nadzeya Goncharenko Khaider 
Departement de Microbiologic et Infectiologie 
Memoire presente a la Faculty de Medecine et des Sciences de la Sante en vue de 
l'obtention du diplome de maitre es sciences (M.Sc.) en Microbiologic, Faculte de 
Medecine et des Sciences de la Sante, Universite de Sherbrooke, 
Sherbrooke, Quebec, Canada, J1H 5N4 
Le cancer epithelial ovarien (CEO) est la principale cause de deces parmi les cancers 
gynecologiques. La majorite des patientes sont diagnostiquees a un stade tardif de la 
maladie. La survie de ces patientes est limitee a cause de la recurrence de la maladie 
devenue resistante a la chimiotherapie. Le developpement de nouveaux agents 
therapeutiques pour le traitement de ce cancer est ainsi une priorite importante dans le 
domaine afin d'ameliorer le taux de survie. La cytokine TRAIL ("TNF-related apoptosis-
inducing ligand") est un nouvel agent prometteur pour le traitement du cancer, incluant le 
cancer ovarien, car il a la capacite unique de declencher l'apoptose dans les cellules 
cancereuses et d'epargner les cellules normales. 
Precedemment, notre laboratoire a montre qu'un nombre significatif de lignees cellulaires 
derivees de cancer ovarien et de cellules provenant de cultures primaires de cancer ovarien 
sont intrinsequement resistantes a l'apoptose induite par le TRAIL. Les mecanismes 
menant a la resistance intrinseque sont largement inconnus. 
Les cellules resistantes au TRAIL montrent souvent une activation accrue de la voie de 
survie PI3K/Akt. En se basant sur les observations que les ascites provenant de cancer 
ovarien induisent une activation de la voie PDK/Akt chez les cellules de cancer ovarien 
sensibles au TRAIL, resultant en une inhibition de l'apoptose produite par le TRAIL, nous 
proposons l'hypothese que l'activation de la voie PI3K/Akt dans les cellules CEO joue un 
role important dans la resistance intrinseque a l'apoptose induite par le TRAIL. 
Les objectifs de mon projet sont de demontrer qu'Akt est implique dans la regulation de 
l'apoptose induite par le TRAIL dans les cellules CEO et de determiner les mecanismes par 
lesquels Akt contribue a la resistance au TRAIL. 
Nous avons demontre que l'activation d'Akt reduit la sensibilite des cellules CEO au 
TRAIL. Les cellules resistantes au TRAIL furent sensibilisees a l'apoptose induite par le 
TRAIL via traitement avec des inhibiteurs de la voie PI3K ou Akt. L'inhibition de la voie 
PDK/Akt n'a pas interferee avec le recrutement et l'activation du pro-caspase-8 au 
DISC (death-inducing signaling complex). Parallelement, une surexpression stable d'Akt 1 
dans les cellules sensibles au TRAIL a resulte en une certaine resistance au TRAIL. Malgre 
le fait que la pro-caspase-8 etait recrutee et activee au DISC dans les lignees cellulaires 
resistantes et sensibles, le clivage de Bid par la caspase-8 apparaissait seulement dans les 
lignees sensibles au TRAIL. L'activation d'Akt dans les cellules sensibles au TRAIL a 
inhibe le clivage de Bid induit par TRAIL. De plus, l'expression de Bid fut diminuee par 
l'activation d'Akt. La depletion de Bid par siRNA dans les cellules de CEO sensibles au 
TRAIL fut associee a une baisse de I'apoptose mediee par TRAIL et une surexpression de 
Bid dans les cellules resistantes au TRAIL resultat en une hausse de I'apoptose mediee par 
TRAIL. 
Dans leur ensemble, ces resultats suggerent qu'Akt est un facteur critique pour la resistance 
intrinseque chez les cellules CEO et qu'un mecanisme important par lequel l'activation 
d'Akt contribue a la resistance au TRAIL, est la regulation de l'expression de la proteine 
pro-apoptotique Bid. 
Suite a ces donnees, nous speculons que l'activation d'Akt pourrait etre un biomarqueur 
potentiel pour predire la reponse des patientes a une therapie basee sur TRAIL et que 
1'inhibition de la voie PI3K/Akt pourrait devenir une des strategies pour surmonter la 
resistance a TRAIL dans le cancer ovarien. 
Mots cles : cancer ovarien epithelial; TRAIL; apoptose; resistance; Bid. 
SUMMARY 
Mechanisms of intrinsic resistance to TRAIL-induced apoptosis among ovarian 
cancer cells 
By 
Nadzeya Goncharenko Khaider 
Departement de Microbiologic et Infectiologie 
Memoire is presented to the Faculte de Medecine et des Sciences de la Sante in order to 
obtain the Diploma of Master of Sciences (M.Sc.) in Microbiology, Faculte de Medecine et 
des Sciences de la Sante, Universite de Sherbrooke, 
Sherbrooke, Quebec, Canada, J1H 5N4 
EOC (epithelial ovarian cancer) is a leading cause of death from gynecological cancers. 
The majority of the patients with EOC are diagnosed at a late stage. The survival of these 
patients is limited due to recurrence of chemotherapy resistant disease. Therefore, the 
development of novel therapeutic agents for the treatment of EOC is urgently needed and it 
is a high priority in the field. TNF-related apoptosis-inducing ligand (TRAIL) is a 
promising novel agent for the treatment of cancer, including EOC, because of its unique 
ability to trigger apoptosis in cancer cells and spare normal cells. 
Our laboratory has previously shown that a significant number of EOC cell lines and 
primary EOC samples are intrinsically resistant to TRAIL-induced apoptosis. The 
mechanisms leading to intrinsic resistance are largely unknown. TRAIL-resistant cells 
often display increased activation of the pro-survival PI3K/Akt pathway. Based on our 
observations that EOC ascites induced activation of the PI3K/Akt pathway in TRAIL-
sensitive EOC cells which resulted in inhibition of the TRAIL-mediated apoptosis, we 
hypothesized that activation of the pro-survival PI3K/Akt pathway in EOC cells plays an 
important role in the resistance to TRAIL-induced apoptosis. 
The objectives of my project were to demonstrate that Akt is implicated in the regulation of 
TRAIL-induced apoptosis in EOC cells and to investigate the mechanisms by which Akt 
contributes to TRAIL resistance. 
We report that Akt activation reduces the sensitivity of ovarian cancer cells to TRAIL. 
TRAIL-resistant cells were sensitized to TRAIL-induced apoptosis by treatment with PI3K 
or Akt inhibitors but inhibition of PI3K/Akt signaling pathway did not interfere with the 
recruitment and processing of the pro-caspase-8 to the death-inducing signaling complex 
(DISC). Conversely, overexpression of Aktl in TRAIL-sensitive cells promoted resistance 
to TRAIL. Despite the fact that TRAIL-induced caspase-8 activation was observed in both 
TRAIL-sensitive and -resistant cell lines, Bid cleavage occurred only in TRAIL-sensitive 
cells. Akt activation in TRAIL-sensitive cells inhibited TRAIL-induced Bid cleavage. 
Furthermore, Bid expression was downregulated by Akt activation. Depletion of Bid by 
siRNA in TRAIL-sensitive EOC cells was associated with a decrease in TRAIL-mediated 
apoptosis and Bid overexpression in TRAIL-resistant cells resulted in increased TRAIL-
mediated apoptosis. 
Altogether, these results suggest that Akt is a critical factor for mediating intrinsic TRAIL 
resistance among EOC cells and that an important mechanism by which Akt activation 
contributes to TRAIL resistance is by regulating the expression of pro-apoptotic protein 
Bid. 
Given these data, we speculate that Akt activation may be a potential biomarker to predict 
patient's response to TRAIL therapy and that the inhibition of the PI3K/Akt pathway can 
become one of the strategies to overcome resistance to TRAIL therapy in ovarian cancer. 
Key words: epithelial ovarian cancer; TRAIL; apoptosis; resistance; Bid. 
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INTRODUCTION 
1. Cancer 
1.1 General remarks 
Cancer is a genetic disease that is responsible for one in eight deaths worldwide (GARCIA 
et al., 2007). The two main characteristics of the cancer are the uncontrolled growth of the 
cells in the human body and the ability of these cells to migrate from the original site and 
spread to distant sites. Cancer is a leading cause of death in Canada. Based on the 2009 
incidence rates, 40% of Canadian women and 45% of men will eventually develop cancer. 
An estimated 1 out of every 4 Canadians are expected to die from cancer. The most 
common types of cancer are lung, breast and prostate cancer (CANADIAN CANCER 
STATISTICS, 2009). 
1.2 The hallmarks of cancer 
Development of cancer involves dynamic changes in the genome. In order to be able to 
transform from normal to malignant, cells can accumulate many genetic alterations during 
lifetime, which explains the dramatic age-dependent escalation in cancer risk. Cancer cells 
acquire a common set of properties such as self-sufficiency in growth signals, evasion of 
programmed cell death (apoptosis), insensitivity to growth-inhibitory signals, limitless 
replicative potential, sustained angiogenesis, and tissue invasion and metastasis. These new 
properties are shared by most types of human tumors (HANAHAN and WEINBERG, 
2000). 
Multiple systems in the cells ensure that the mutations are rare events. So rare that the 
multiple mutations known to be present in tumor cell genomes are highly unlikely to occur 
during human lifetime. Yet cancers do appear because genomes of tumor cells have 
increased mutability due to malfunction of specific components of genomic caretaker 
2 
systems. Not surprisingly, in addition to six classical hallmarks of cancer mentioned above, 
a set of additional hallmarks were proposed: DNA damage stress, proteotoxic stress, 
mitotic stress, metabolic stress, oxidative stress and evading immune surveillance (LUO et 
ai, 2009) (Figure 1). 
Evading Self-sufficiency in 
apoptosls growth signaf 
Tissue invasion Insensitivity to 
& metastasis Jg WK^m Aanti-growth signals 
s* \  n&k 
Sustained 'Survival/Proliferation" 
angiogenesis environmentsJ potent^  
C Hypoxia Senescence Low 
Evading immune ROS 
Aneuptoidy 
/ \ 
Metabolic 
DNA damage 
stress 
Oxidative 
strass 
Figure 1. The hallmarks of cancer (LUO et al, 2009). In addition to the six hallmarks of 
cancer originally proposed by Hanahan and Weinberg (top half, white symbols) and 
evasion of immune surveillance proposed by Kroemer and Pouyssegur, a set of additional 
hallmarks were highlighted (lower half, colored symbols). 
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1.2.1 Self-sufficiency in growth signals 
Normal cells require mitogenic growth signals to proliferate. These signals are transmitted 
into the cells by transmembrane receptors that bind number of signaling molecules: GFs 
(growth factors), components of ECM (extracellular matrix), and cell-to-cell 
adhesion/interaction molecules. Normal cells can not proliferate in absence of such 
stimulatory signals. Tumor cells generate many of their own GFs, thereby reducing their 
dependence on stimulation from their normal tissue microenvironment (FEDI et al, 1997). 
Cancer cells can achieve independence from exogenously derived GFs by three common 
molecular strategies, involving alterations of extracellular growth signals, or transcellular 
transducers of those signals, or intracellular molecules that translate those signals into 
action. 
Successful tumor cells can influence their normal neighbours by inducing them to release 
growth-stimulating factors (SKOBE and FUSENIG, 1998). In addition, the inflammatory 
cells attracted to sites of neoplasia may promote (rather than eliminate) cancer cells 
(HUDSON et al., 1999; COUSSENS et al., 1999). Tumor cells produce various cytokines 
and chemokines that attract the diverse leukocyte population — for example, neutrophils, 
dendritic cells, macrophages, eosinophils and mast cells, as well as lymphocytes — all of 
which are capable of producing an assorted array of cytokines, cytotoxic mediators 
including reactive oxygen species, serine and cysteine proteases, MMPs and membrane-
perforating agents, and soluble mediators of cell killing, such as TNF-a, interleukins and 
interferons (KUPER et al., 2000). But the metabolic microenvironment of tumor cells may 
inhibit the function of antitumor immune effectors such as cytotoxic T lymphocytes (CTLs) 
and natural killer (NK) cells while attracting inflammatory cells that participate in tumor 
progression such as tumor-associated macrophages (TAMs) (WAHL and KLEINMAN, 
1998). TAMs and tumor cells produce IL-10, which effectively blunts the anti-tumour 
response by cytotoxic T cells (KROEMER and POUYSSEGUR, 2008). TAMs facilitate 
angiogenesis, promote tumor cell migration, and exert local immunosuppressive effects 
4 
(CONDEELIS and POLLARD, 2006). In addition, acidification of tumor beds can inhibit 
the activity of NK cells (LARDNER et al., 2001). 
The cell surface receptors that transduce growth-stimulatory signals into the cell are often 
overexpressed in cancers. Cancer cells can also switch the types of the extracellular 
receptors (integrins) they express, favouring the ones that transmit pro-growth signals 
(GIANCOTTI and RUOSLAHTI, 1999). 
A number of intracellular growth signaling pathways are deregulated in cancer cells. One of 
them is SOS-Ras-Raf-MAP kinase mitogenic cascade (HUNTER, 1997) which is linked to 
a variety of cross-talking pathways. For example, the direct interaction of Ras protein with 
the survival-promoting PI3K/Akt pathway enables GFs to stimulate survival signals within 
the cell (DOWNWARD, 1998). 
1.2.2 Insensitivity to antigrowth signals 
Within a normal tissue, multiple antiproliferative signals can block proliferation by two 
distinct mechanisms. Cells may be forced out of proliferative cycle into the quiescent (GO) 
state from which they can recover upon GFs stimulation. Alternatively, cells may be 
induced to permanently exit their proliferative state by entering into a postmitotic state. For 
example, when they are terminally differentiated, cells permanently enter GO phase but 
continue to perform their main functions for the rest of the organism's life (HANAHAN 
and WEINBERG, 2000). 
Tumor cells use various strategies to avoid terminal differentiation. The classical example 
is negative regulation of pRb tumor suppressor gene which normally blocks proliferation 
by altering function of E2F transcription factor that is essential for progression from G1 to 
S phase (WEINBERG, 1995). Another strategy is overexpression of the c-Myc oncoprotein 
that drives cell growth and proliferation (FOLEY and EISENMAN, 1999). 
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1.2.3 Resistance to apoptosis 
The apoptotic program is present in latent form in almost all cell types. Intracellular sensors 
monitor the cell's well being and activate the death pathway in response to detected diverse 
abnormalities such as DNA damage, signaling imbalance provoked by oncogene action, 
survival factors insufficiency, or hypoxia (EVAN and LITTLEWOOD, 1998). 
Resistance to apoptosis is acquired by cancer cells through occurring loss of pro-apoptotic 
regulators such as p53 tumor suppressor gene that is seen in more than 50% of human 
cancers (HARRIS, 1996). Additionally, constitutive activation of the PI3K/Akt pro-
survival pathway that counteracts apoptosis is often observed in cancer cells (EVAN and 
LITTLEWOOD, 1998; DOWNWARD, 1998; CANTLEY and NEEL, 1999). Possible 
mechanisms of action are described in section 4.3.1 and 4.3.2. 
1.2.4 Limitless replicative potential 
Once normal cell populations have progressed through a certain number of doublings, they 
stop growing (a process termed senescence). This process in independent of cell-to-cell 
signaling pathways described above. The number of cell divisions is controlled by the end 
of the chromosomes (telomeres). Telomeres keep chromosomes protected and prevent them 
from fusing into rings or binding with other DNA. After each cell replication 50 to 100 bp 
of telomeric DNA are lost. As human telomeres grow shorter, eventually cells reach the 
limit of their replicative capacity and progress into senescence. However, further cell 
proliferation can be achieved by inactivation of p53 and pRb pathways. Cells entering 
proliferation after inactivation of p53 and pRb pathways undergo crisis. Crisis is 
characterized by gross chromosomal rearrangements and genome instability, and almost all 
cells die (COUNTER et al., 1992). But 85-90% of tumor cells are able to maintain telomere 
length by upregulating expression of the enzyme telomerase that adds hexanucleotide 
repeats at the end of telomeric DNA, which in turn permits unlimited multiplication of cells 
(BRYAN and CECH, 1999). 
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1.2.5 Sustained angiogenesis 
The nutrients and oxygen supply by the vasculature are crucial for cell function and 
survival. The process of new blood vessels formation (angiogenesis) is carefully regulated 
in normal tissues. Counterbalancing positive and negative signals encourage or block 
angiogenesis. Some examples of angiogenesis-initiating factors are VEGF (vascular 
endothelial growth factor) and FGF1/2 (basic fibroblast growth factors) (VEIKKOLA and 
ALITALO, 1999) and one of the inhibitors is thrombospodin-1 (BULL et al., 1994). 
Tumors appear to activate the angiogenic switch by changing the balance of angiogenesis 
inducers and countervailing inhibitors (HANAHAN and FOLKMAN, 1996). 
1.2.6 Tissue invasion and metastasis 
The distant settlements of tumor cells (metastases) are the cause of 90% of human cancer 
deaths (SPORN, 1996). The capability for invasion and metastasis enables cancer cells to 
escape the primary tumor mass and form new tumors in other parts of the body where, at 
least initially, nutrients and space are not limiting. Several classes of proteins are involved 
in this process: the cell-cell adhesion molecules (CAMs), the integrins, which link cells to 
extracellular matrix, the cadherins and extracellular proteases (WOODHOUSE et al., 
1997). 
The most widely observed alteration in cell-to-environment interactions in cancer involves 
E-cadherin, a homotypic cell-to-cell interaction molecule expressed on cell surface of 
epithelial cells. E-cadherin function is apparently lost in a majority of epithelial cancers 
(CHRISTOFORI and SEMB, 1999) with the exception of epithelial ovarian cancer. Up-
regulation of E-cadherin is an early defining event in ovarian cancer and may play a 
significant role in the initial development of the primary ovarian tumor (ANSENBERGER 
etal., 2009). 
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Another general parameter of the invasive metastatic capability involves extracellular 
proteases (COUSSENS and WERB, 1996). Protease genes are upregulated, protease 
inhibitor genes are downregulated, and inactive zymogen forms of proteases are converted 
into active enzymes in cancer cells (STETLER-STEVENSON, 1999). 
1.2.7 Additional hallmarks: the stress phenotypes of cancer 
DNA damage stress: Tumors pass through stages of extreme genomic instability that result 
in accumulation of point mutations, deletions, complex chromosomal rearrangements, and 
extensive aneuploidy (HARTWELL and KASTAN, 1994). This is due to a constitutive 
level of endogenous DNA damage, which leads to activation of the DNA damage 
checkpoint and thereby to apoptosis or cell cycle arrest. Cancer cells are able to overcome 
the antiproliferative effects of DNA damage, continuing to replicate in the presence of 
damage. 
Proteotoxic stress: The long-term health of the cell has been linked to protein quality 
control. Under optimal conditions this is accomplished by protein homeostasis, a highly 
complex network of molecular interactions that balances protein biosynthesis, folding, 
translocation, assembly/disassembly, and clearance. If unattended, misfolded proteins can 
result in severe molecular damage to the cell. Adaptation and survival requires the ability to 
sense damaged proteins and to coordinate the activities of proteotoxic stress response 
pathways and chaperone networks. Yet, despite the abundance and apparent capacity of 
chaperones and other components of homeostasis to restore folding equilibrium, cancer 
cells have been shown to contain increased amount of toxic, unfolded protein aggregates 
(DENOYELLE etal., 2006). 
Mitotic stress: The completion of spindle formation is a crucial transition point in the cell 
cycle called the spindle assembly checkpoint. If some chromosomes are not properly 
attached to the mitotic spindle by the time of this checkpoint, the onset of anaphase will be 
delayed. A subset of tumors have increased defects in mitotic proteins that execute 
chromosome segregation and defects in the spindle assembly checkpoint, which 
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coordinates anaphase entry with the proper alignment of chromosomes on the mitotic 
spindle (CAHILL et al., 1998). 
Metabolic stress: Normal cells carry out mitochondrial oxidative phosphorylation to 
produce ATP. Most cancer cells produce energy by less efficient method of glycolysis and 
secrete a large amount of lactic acid, even under high oxygen conditions 
(DEBERARDINIS et al., 2007) which provides several advantages to the tumor including 
adaptation to a low oxygen environment and acidification of the surrounding 
microenvironment, which promotes tumor invasion and suppresses immune surveillance 
(GATENBY and GILLIES, 2004). 
Evading immunosurveillance: The metabolic microenvironment of tumor cells may inhibit 
the function of antitumor immune effectors such as cytotoxic T lymphocytes (CTLs) and 
natural killer (NK) cells while attracting inflammatory cells that participate in tumor 
progression. Tumor-associated macrophages (TAMs) are often enriched in hypoxic and 
tumor perinecrotic areas and constitute a negative prognostic marker. TAMs facilitate 
angiogenesis, promote tumor cell migration, and exert local immunosuppressive effects 
(CONDEELIS and POLLARD, 2006). 
2. Ovarian cancer 
2.1 General remarks 
Ovarian cancer occurs in approximately 204 000 women worldwide each year (JEMAL et 
al, 2008). Globally it claims 125 000 lives per year, making it the seventh leading cause of 
cancer-related deaths among women. Over 2500 Canadian women are diagnosed every 
year; and every year 1700 women succumb to this disease (CANADIAN CANCER 
STATISTICS, 2009). Despite its relatively low incidence rate, ovarian cancer is an 
extremely lethal disease. Its high mortality is mostly due to the difficulty in diagnosing the 
disease at early stage. Although the five years survival rate for stage I ovarian cancer is 
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>90%, stage I diagnoses are more often the exception than the rule. Most patients (75%) 
present with advanced stage (III/IV) tumors, for which the five year survival rate is at best 
30% (BOYLE and LEVIN, 2008). Consequently, ovarian cancer is frequently nicknamed 
the "silent killer". 
2.2 Risk factors 
Age: Epithelial ovarian cancer (EOC) is a disease of older age. With the exception of the 
hereditary forms of the disease, ovarian cancer is uncommon before the age of 40 years 
(COLOMBO et al, 2006). 
Environmental and hormonal factors: Significant geographic and ethnic variations in 
ovarian cancer incidence have been observed. Rates are highest for Caucasian women in 
industrialized countries of North America and Europe which could be explained by 
differences in reproductive pattern and diet. Epidemiological research has shown that 
multiple pregnancies, lactation, and oral contraceptive use are associated with a reduced 
risk of developing ovarian cancer (TORTOLERO-LUNA and MITCHEL, 1995). 
Conversely, nulliparity, early menarche, and late menopause are associated with an 
increased risk (OZOLS et al, 2004). Studies that analyzed dietary factors found that diet, 
which is high in meats and low in vegetables, may be positively associated with ovarian 
cancer incidence. Vegetable, but not fruit, consumption may be associated with beneficial 
effects (SCHULZ et al, 2004). Exposure to talc or asbestos may represent factors that may 
initiate ovarian cancerogenesis, inducing a chronic inflammation of ovarian epithelium 
(COLOMBO et al, 2006). 
Hereditary predisposition: A strong family history of either breast or ovarian cancer is the 
most important risk factor for the development of EOC. Approximately 10% to 15% of all 
EOC have a hereditary predisposition (PAL et al, 2005). Hereditary ovarian cancer is seen 
commonly within the breast-ovarian cancer family syndrome because of mutations in 
BRCAlor BRCA2 (GARBER and OFFIT, 2005). BRCA1 and BRCA2 genes are located 
on chromosomes 17q and 13q respectively. The proteins encoded by these genes are 
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implicated in DNA repair (SCULLY et al, 1996). Ovarian cancer has also been seen in 
families with hereditary non-polyposis colon cancer (Lynch syndrome II), along with an 
excess of colorectal and endometrial cancers. Lynch syndrome II results from inherited 
mutation in DNA mismatch repair genes (LINDOR et al., 2006). 
2.3 Diagnostic cues 
Symptoms: Ovarian carcinoma does not produce specific symptoms. Abdominal discomfort 
or vague pain, abdominal fullness, bowel habit changes, constipation, early satiety, 
dyspepsia, and bloating, urinary frequency are frequent presenting symptoms. Often these 
symptoms occur when the disease is already spread throughout the abdominal cavity 
(ALETTI et al., 2007). 
Signs: The most important sign of ovarian carcinoma is the presence of a pelvic mass on 
physical examination. The ovaries are a pair of tiny organs, only 2-4 cm in diameter, 
suspended on either side of uterus and not readily accessible by pelvic examination unless 
significantly enlarged (Figure 2). By definition, a stage I tumor is confined to the ovary and 
is unlikely to be noticed without the aid of a sensitive screening test. The best tools 
currently available are transvaginal sonography (TVS) and serum biomarker testing 
(KARST and DRAPKIN, 2010). 
2.3.1 Serum biomarkers 
The most well-studied ovarian cancer biomarker is CA-125, a high molecular weight 
transmembrane glycoprotein expressed by coelomic- and Mullerian-derived epithelia. It is 
not expressed by normal ovarian epithelium (KABAWAT et al., 1983). CA-125 is detected 
at low levels (<35 U/ml) in the serum of healthy individuals but is elevated in 50% of stage 
I ovarian cancer patients and 90% of advanced-stage patients (BAST et al., 2002). 
However, it was later discovered that serum CA-125 can also be increased in different 
benign conditions (such as pelvic inflammatory disease, endometriosis, uterine fibroids, 
and ovarian cysts) making false positivity a problem (MEDEN and FATTANI-MEIODI, 
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1998). In addition, 25% of ovarian carcinomas are CA-125 negative (MANN et al, 1988). 
Although, CA-125 has not demonstrated adequate sensitivity to support its use in screening 
for early-stage ovarian cancer, it remains a valuable tool for monitoring response to 
chemotherapy and for detecting disease relapse following treatment (GADDUCCI et al, 
1995). Recent studies identified several new candidates for markers such as LPA 
(lysophosphatidic acid) that is found to be elevated in serum and ascites fluid (XU et al, 
1998), mesothelin (SCHOLLER et al., 1999), HE4 (SCHUMMER et al., 1999), 
osteopontin (MCINTOSH et al, 2004), VEGF and IL8 (LU et al, 2004) and macrophage 
colony-stimulating factor (XU et al., 1991). 
2.4 Grading of ovarian cancer 
90% of ovarian cancers arise from cells that make up the epithelial layer that covers the 
surface of the ovaries. Other two types are germ cell tumors and stromal tumors. Stromal 
tumors arise in hormonally active elements within the connective tissue stroma of the 
ovary. Germ cell tumors and stromal tumors each account for approximately 5% of ovarian 
cancers (GERSHENSON et al., 2005). Epithelial ovarian cancer (EOC) represents a 
heterogeneous group of neoplasm that exhibit a wide range of tumor morphologies, clinical 
manifestations, and underlying genetic alterations. 
Ovarian tumors are surgically staged to determine how far they have extended beyond 
ovary. Stage I indicates confinement to ovary. Stage II tumors extended beyond ovary to 
adjacent pelvic structures such as fallopian tube or uterus. Stage III indicates metastasis to 
the peritoneum and/or regional lymph nodes. Stage IV tumors have metastasized beyond 
the peritoneum to distant sites. 
World health organization (WHO) recognizes eight histologic tumor subtypes of EOC: 
serous, endometrioid, mucinous, clear cell, transitional cell, squamous cell, mixed 
epithelial, and undifferentiated (TAVASSOLI and DEVILEE, 2003). The three most 
common (serous, endometrioid, and mucinous) are characterized by their morphological 
resemblance to various mucosal tissues of female reproductive tract, all of them exhibit 
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Mollerian differentiation (Figure 2). It has been estimated that 50% of malignant ovarian 
tumors are serous carcinomas, while 25% are endometrioid, 10% are mucinous and only 
5% are clear cell carcinomas (CHEN et al., 2003). 
Journal of Oncology 
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Figure 2. The major histologic subtypes of ovarian carcinoma (KARST and DRAPKIN, 
2010). Serous carcinomas resemble fallopian tube epithelium, endometrioid carcinomas 
resemble endometrial glands, and mucinous carcinomas resemble endocervical epithelium. 
Photographs show representative tumor sections stained with hematoxylin and eosin. The 
shaded circle represents the general anatomical location from which ovarian carcinomas are 
thought to arise. The pink and blue entities within the cross-sected ovary represent 
maturing ovarian follicles. 
13 
Within each subtype, tumors are further described as benign (localized tumors that has not 
spread to other parts of the body), malignant (tumors that invade and damage other tissues 
and organs), or borderline (semimalignant tumors which are considered to have low 
malignant potential) and, depending upon tumor subtype, classified as low-or high-grade. 
Low grade tumors are composed of uniform cells that look very like normal cells of ovary 
with mild or moderate nuclear atypia and low mitotic index. They are associated with a 
serous neoplasm of low malignant potential. High grade tumors are composed of 
pleomorphic cells that look very abnormal with marked nuclear atypia and high mitotic 
index and associated with high malignant potential (MALPICA, 2008). 
2.5 Role of EOC ascites in promotion of tumor cell survival 
Epithelial ovarian cancer (EOC) is highly metastatic cancer characterized by widespread 
intraperitoneal dissemination and ascites formation (an abnormal accumulation of fluid in 
the abdomen) (SHEN-GUNTHER and MANNEL, 2002). EOC ascites may contain a 
variety of cytokines, growth factors, bioactive lipids, hormones, and components of ECM 
which contribute to cancer cell migration and invasion (YAMADA et al., 2004; GRAVES 
et al., 2004). Our laboratory has demonstrated that EOC ascites contribute to tumor cell 
survival by activating the pro-survival PI3K/Akt pathway (LANE et al., 2007; LANE et al., 
2010). Activation of a number of cell surface receptors may contribute to the activation of 
PI3K/Akt pathway (Figure 3). 
Ovarian cancer ascites contains growth factors that could potentially activate tyrosine 
kinase receptors (ABENDSTEIN et al., 2000; MIYAMOTO et al., 2004). The binding of 
growth factors to tyrosine kinase receptors stimulates the phosphorylation of 
phosphatidylinositol 3-kinase (PI3K), which in turn leads to Akt activation (Figure 3). 
Epidermal growth factor receptor (EGFR), platelet-derived growth factor receptor 
(PDGFR), and Her2/neu are commonly overexpressed in EOC and are involved in inducing 
the tumor cell proliferation (ALPER et al., 2001; MATEI et al., 2006). 
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PI3K may also become activated through G-protein-coupled receptors (GPCR) (Figure 3). 
G-protein-coupled receptors regulate a variety of cell functions including cell proliferation, 
survival, and motility, and have recently emerged as important players in tumor growth and 
survival (MILLS and MOOLENAAR, 2003). One of the ligands of G-protein coupled 
receptors is the lysophosphatidic acid (LPA) that has been shown to induce cell survival 
signaling through the PI3K/Akt pathway in ovarian cancer cells (KANG et al, 2004). 
Ascites fluid contains significant levels of LP A, which exceed levels required to activate 
LPA receptors (YAMADA et al, 2004). 
PI3K/Akt pathway may also become activated by the interactions between extracellular 
matrix proteins (ECM) with cell surface integrins (HYNES, 1992). Integrins transmit 
signals directly through ligation-dependent recruitment of the focal adhesion kinase (FAK) 
leading to the activation of several cell-signaling pathways including the PI3K/Akt pathway 
(STUPACK and CHERESH, 2002). 
Our laboratory investigated the mechanisms by which EOC ascites activates Akt in EOC 
cells and we demonstrated that survival promoting activity of ascites was not affected by 
inhibitors of GF receptors including EGFR, VEGFR, FGFR, Her2/neu, and IGF-R1. We 
also concluded that LPA does not contribute to the pro-survival activity of EOC ascites. 
However, the integrin pathway was involved in ascites-mediated protection from TRAIL-
induced apoptosis. We demonstrated that ovarian cancer ascites induces FAK and Akt 
activation in an av|35 integrin-dependent pathway (LANE et al, 2010). 
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Figure 3. The mechanisms of PDK/Akt pathway activation by ascites. Ovarian cancer 
ascites contains a number of growth factors that could potentially activate tyrosine kinase 
receptors such as EGFR, PDGFR, Her2/neu, etc. Ascites fluid also contains bioactive 
lipids, such as LPA, which is one of the ligands of G-protein coupled receptors (GPCR). 
Activation of these receptors can result in downstream activation of PI3K/Akt. Akt 
pathway can also become activated due to the interactions between extracellular matrix 
(ECM) proteins with cell surface integrins. Such interactions activate the focal adhesion 
kinase (FAK) and subsequently the PI3K/Akt pathway. 
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2.6 Origin of ovarian cancer 
Several hypotheses have been proposed about the underlying physiological processes that 
increase risk of the ovarian cancer (Table 1) (LANDEN et al., 2008). 
Table 1. Hypotheses oil physiologic susceptibilities to epithelial ovarian cancer 
Gonadotropin stimula­
tion 
Stimulatory effect of FSH and LH 
promote growth, increased eel 
c&vtstons: am) mutations 
Increased EOC risk with infertility. PCOS; 
Decreased risk with progesterotvonly 
OCPs, FSH upreguiates many oncogenes 
omotes growth in preclinical models 
Inflammation Damaged OSE with ovulation 
induces inflammation. which pro -
motes reconstruction and mutation 
susceptibility 
Possible reduced risk with NSAID use. 
increased risk with talc or asbestos; 
abundanceof inflammatory mediators 
in tumors 
Abbreviations OSE. ovarian surface epithelium. EOC. epithelial ovarian cancer. OCP. oral contracep­
tive Difl. FSH. follicle-stimuli no hormone. LH. tutemrarwhormone. PCOS. polycystic ovarian syndrome 
2.6.1 Ovarian surface epithelium and cortical inclusion cyst 
It is widely thought that most ovarian cancers develop from the surface epithelium (OSE). 
OSE is a flat-to-cuboidal layer of uncommitted mesothelial cells covering the. exterior 
surface of the ovary. During ovulation, follicular rupture and oocyte release causes physical 
trauma upon the ovarian surface, creating a breach in OSE that must be repaired. Over the 
course of a woman's life, this process of damage and repair is repeated multiple times. 
Accordingly OSE exhibit a high degree of plasticity that facilitates tissue remodeling 
(KRUK et al, 1994). In addition to physical trauma, OSE cells are subjected to ovulation-
associated inflammatory cytokines and oxygen species that are capable damaging DNA 
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(MURDOCH and MARTINCHICK, 2004). Furthermore, as women age, the ovarian 
surface develops numerous invaginations into the cortical stroma. These invaginations 
frequently pinch off and become entrapped within the stroma, forming circular OSE-lined 
structure termed "cortical inclusion cysts" (CICs) (Figure 4). Once inside the ovary, the 
epithelial cells lining CICs are exposed to a new hormone-rich milieu that is thought to 
induce a differentiation into more complex epithelium resembling that of MUllerian-derived 
organs (DRAPKIN and HECHT, 2006). If the epithelial cells also happen to harbour 
unresolved DNA damage, they may be prime targets for neoplastic transformation, 
eventually giving rise to ovarian carcinomas. 
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Figure 4. Model of the development of an EOC tumor (FARLEY et al, 2008). Incessant 
ovulation and wound repair increases the risk of genetic abnormalities, leading to changes 
in epithelial cells lining the Mullerian inclusion cyst. Stromal microenvironment in the 
forms of activated fibroblast formation, microvessel proliferation, and growth factors 
contributes to dynamic formation and eventual malignant transformation. 
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2.6.2 Two pathway model of ovarian carcinogenesis 
The two pathway model of ovarian carcinogenesis proposed by KURMAN and SHIH 
(Figure 5) takes into account the diverse nature of ovarian cancer and correlates the clinical, 
pathological, and molecular features of the disease. In this model, ovarian tumors are 
divided into type I and II. Type I tumors are slow growing, generally confined to the ovary 
at the diagnosis, and develop from well-established precursor lesions. Type I tumors 
include low-grade micropapillary serous carcinoma, mucinous, endometrioid, and clear cell 
carcinomas. They are genetically stable and characterized by mutations in number of 
different genes including KRAS, BRAF, PTEN, and (3-catenin. Mutations of KRAS and 
BRAF lead to the activation of MAPK signaling pathway (PEYSSONNAUX and 
EYCHENE, 1996). PTEN mutations result in constitutively PI3K/Akt signaling (OBATA 
etal., 1998). 
Type II tumors are rapidly growing highly aggressive neoplasms for which well-defined 
precursor lesions have not been described. Type II tumors include high-grade serous 
carcinoma, malignant mixed mesodermal tumors, and undifferentiated carcinomas. This 
group has a high level of genetic instability and is characterized by mutation of TP53. 
These tumors may also exhibit gene amplification and overexpression of HER2/neu 
oncogene (10-20%) (ROSS et al., 1999) and Akt2 oncogene (12-18%) (CHENG et al, 
1992) and they are rarely only confined to the ovary. 
19 
Serous cystadenoma 
KRAS KRAS 
BRAF " 
Ovarian surface inclusions 
Peritoneum 
Fallopian tube 
APST 
1 
MPSC 
APST 
I 
MPSC 
Molecular 
genetic 
changes 
Low-grade 
serous CA 
(grade 1) 
High-grade 
serous CA 
(grade 3) 
High-grade 
serous CA 
(grade 2) 
High-grade 
serous CA 
(grade 3) 
KRAS/BRAF Mutations Mutations Wild-type Wild-type 
TPS3 Wild-type Wild-type Mutations Mutations 
~Y~~ 
Type I Type 
Figure 5. Two pathway model of ovarian carcinogenesis (KURMAN and SHIH, 2008). 
Proposed pathways for the development of different types of serous carcinoma. APST 
indicates atypical proliferative serous tumor; MPSC, micropapillary serous carcinoma. 
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2.6.3 Fallopian tube as a site of origin 
Several recent studies have demonstrated that many high-grade serous ovarian tumors may 
actually be of tubal origin, arising from the distal region of the fallopian tube, but then 
quickly spreading to nearby ovary (MEDEIROS et al., 2006; KINDELBERGER et al., 
2007; LEE et al., 2007). The fimbria (the end of the Fallopian tube (Figure 2)) lies in 
extremely close proximity to ovarian surface epithelium and is therefore exposed to the 
same inflammatory and potentially carcinogenic microenvironment. Lee et al. formulated a 
model of ovarian cancer which incorporates the fimbria as a major site of origin for serous 
carcinomas. This model states that there are two distinct pathways leading to ovarian 
tumorigenesis. The first route is the traditional OSE-CIC pathway which leads to formation 
of Kurman's and Shin's "Type I" tumors. The second pathway involves the fallopian tube 
fimbria, where a combination of TP53 mutation and genotoxic stress leads to the clonal 
expansion of secretory epithelial cells, forming a pre-neoplastic precursor lesion or "p53 
signature". Additional genetic "hits" in the absence of functional TP53 enable these cells to 
acquire a proliferative capacity, facilitating the progression of tubal intraepithelial 
carcinoma (TIC) (Figure 6). This second pathway leads to formation of Kurman's and 
Shin's "Type II" tumors. 
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Figure 6. Fallopian tube as a site of origin (KARST and DRAPKIN, 2010). The fallopian 
tube epithelium (FTE) is composed of a single layer of ciliated and secretory cells that are 
exposed to ovulation-associated inflammatory cytokines and reactive oxygen species 
(ROS). Repetitive genotoxic stress causes DNA damage and induces p53 mutation, leading 
to the clonal expansion of normal looking FTE cells of secretory phenotype. These 
damaged cells stain strongly for p53 ("p53 signature"). Further genetic "hits" enable cells 
to acquire a proliferative capacity, giving rise to tubal intraepithelial carcinoma (TIC). As a 
TIC progresses to invasive serous carcinoma, malignant cells are exfoliated from the 
fimbria and they may spread rapidly to the surface of the peritoneum and/or ovary. 
Exfoliation may also occur from TICs prior to fimbrial invasion. 
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2.7 Current treatment of EOC and resistance 
The bilateral salpingo-oophorectomy (BSO) is generally recommended for women with 
high risk of developing ovarian cancer (with a known germline mutations of BRCA1 and 
BRCA2) at approximately 35 to 40 years of age as apart of the prophylactic treatment 
(NCCN, 2005). Although prophylactic BSO reduces the risk of ovarian cancer by more 
than 90%, high-risk patients with BRCA1 and BRCA2 mutations can still develop primary 
peritoneal cancer, which develops in 4% to 5% of women at 20 years after BSO (FINCH et 
al., 2006). 
The standard treatment for early-stage ovarian cancer patients is typically cytoreductive 
surgery. Stage I patients with favourable prognosis factors have more than 90% cure rate 
with surgery alone. Early-staged patients with unfavourable prognostic features (such as 
poorly differentiated tumors or evidence of spread) have 70 to 80% cure rate (OZOLS et 
al., 2004). 
After completion of surgery, patients with advanced disease require chemotherapy or 
radiotherapy. EOC is considered to be a chemosensitive neoplasm, with initial overall 
response rates to systemic therapy exceeding 80% when integrated with surgery. However, 
among women with advanced stage disease at diagnosis, long term survival remains poor 
due to eventual tumor recurrence and emergence of drug-resistant disease. Combination 
chemotherapy using paclitaxel with a platinum-based regimen is currently the standard 
first-line treatment for ovarian cancer (COLOMBO et al., 2006). Whereas cisplatin-
paclitaxel combination chemotherapy has shown significant efficacy over previous drug 
combinations, 20-30% of patients fail to respond to this combination and 90% of patients 
that initially responded to therapy will eventually develop chemotherapy-resistant disease 
(MCGUIRE et al., 1996). Patients that do not respond to the first-line chemotherapy are 
given second-line and third-line regimens of chemotherapy in an attempt to prolong life and 
palliate symptoms. Second-line chemotherapeutic agents are rarely curative, with initial 
response ranging from 10-33% (JUDSON et al, 1999). The discovery of novel and 
effective therapy against chemotherapy-resistant ovarian cancer remains a high priority. 
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2.7.1 Mechanisms of resistance to chemotherapy 
A wide range of metabolic or structural properties within tumour cells may lead to drug 
resistance. The identified mechanisms include: decreased drug uptake, increased drug 
efflux, increased repair of DNA damage induced by chemotherapy and reduced ability to 
undergo apoptosis (GOLDENBERG et al., 1998). In addition, because cancer cells are 
heterogeneous, more than one mechanism of drug resistance may be present in any 
particular case. 
Initially sensitive tumor cells may become resistant to drugs during repetitive 
chemotherapy, which is so called acquired (induced) resistance, or they may be resistant 
without previous exposure to drugs- intrinsic resistance. Cells with acquired drug 
resistance can be produced experimentally by the successive exposure of parent cells to a 
particular drug in vitro (BOSCH and CROOP, 1996; Lane et al., 2006). Several 
mechanisms of acquired drug resistance have been demonstrated, including reduced 
accumulation of drug, changes in the expression of enzymes involved in the glutathione 
detoxification pathway, alterations in DNA repair, cell cycle checkpoints and ratio of pro 
and anti-apoptotic Bcl-2 family members (Figure 7). In contrast to acquired drug resistance, 
few studies have examined the mechanisms responsible for intrinsic drug resistance. The 
reason why some tumor cells are inherently resistant without previous drug treatment is not 
known. In addition, importance of the de-novo (environment-mediated) drug resistance has 
been acknowledged. This type of resistance is mediated by tumor microenvironment which 
represents a rich source of both soluble factors and components of ECM, both of which can 
favour cell survival following drug exposure. Mechanisms associated with de-novo drug 
resistance may contribute to the failure to eliminate minimal residual disease and facilitate 
the emergence of acquired drug resistance (MEADS et al., 2009; LANE et al., 2010; 
KERBEL et al., 1994). 
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Figure 7. Acquired drug-resistant models possess multiple drug-resistance 
mechanisms (HAZLEHURST et al, 2003). These mechanisms include: (a) decreased 
intracellular concentration of the drug characteristic of overexpression of drug transporters; 
(b) alterations in the drug target such as point mutations or overexpression of the target; (c) 
increased detoxification of the drug such as glutathione conjugation; (d) changes in the 
repair of DNA damage induced by the drug (e) alterations in the cell cycle checkpoint such 
as p27Kipl or p21; (e) changes in the ratio of pro and anti-apoptotic Bcl-2 family members. 
The ability of most types of cancer to metastasize was also linked to their capacity to 
express resistance to anti-cancer drugs, including all major classes of drugs used in 
chemotherapy. Expression of certain dominantly acting oncogenes or altered expression of 
tumor suppressor genes can enhance not only tumor cell growth and malignant 
25 
aggressiveness, but also the relative expression of drug resistance (HENNEQUIN et al, 
2003). Some of these genetic alterations, mutations of suppressor gene p53 being a good 
example, often occur in more advanced stages of the disease (LASSAM et al., 1993) and 
are relevant to acquisition of malignant properties and also drug resistance. 
Interestingly, a number of studies demonstrated connection between increased activation of 
the pro-survival PI3K/Akt pathway in ovarian cancer cells and resistance to chemotherapy. 
In vivo and in vitro studies demonstrated that inhibition of PI3K enhanced paclitaxel-
induced apoptosis in the human ovarian cancer cells (HU et al., 2002). XIAP (X-linked 
inhibitor of apoptosis protein), Akt2 and p53 are important mediators of chemoresistance in 
EOC. Inhibition of XIAP and/or Akt expression/function is considered to be effective of 
overcoming chemoresistance in EOC cells (FRASER et al., 2003). Targeting PI3K/Akt 
pathway has been shown to enhance sensitivity to docetaxel in breast and ovarian cancer 
(XING et al., 2008). Recent study demonstrated that Akt confers resistance to cisplatin, by 
modulating cisplatin-induced, p53-dependent c-FLIP (FLICE-inhibitory protein) 
ubiquitination (ABEDINI et al., 2009). Combined treatment of carboplatin and PI3K 
inhibitor LY294002 has been demonstrated to effectively decrease ovarian tumor 
progression (WESTFALL and SKINNER, 2005). However, another study indicates that 
efficacy of LY294002 may be greatly affected by the tumor p53 status (BAR et al., 2005). 
2.7.2 Targeted therapies for ovarian cancer 
Despite evidence of considerable heterogeneity in their histological phenotypes and 
molecular profiling, most cases of ovarian cancer are treated in a similar fashion. It became 
apparent that the focus should be towards the development of new targeted therapies 
capable of exploiting molecular and genetic characteristics of individual tumor subtypes. At 
the moment, there is rapid development of novel compounds, including antiangiogenic 
reagents, humanized monoclonal antibodies, selective hormonal agents, and small 
molecules that target key components in signal transduction pathways associated with cell 
growth, tumor vascularity, and invasive potential. 
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A number of studies have focused on the epidermal growth factor receptor (EGFR), which 
is overexpressed in 30 to 70% of EOC (BASELGA, 2002). EGFR inhibitors such as 
cetuximab, ABX-EGF, erlotinib have been evaluated in clinical trials (FINKLER et al, 
2001). In spite of encouraging preclinical models, early results from large trials have not 
shown a benefit (OZOLS et al, 2004). 
Vascular endothelial growth factor (VEGF) has a key role in ascites formation. Antibody 
against VEGF has been shown to prevent and even reverse ascites formation in preclinical 
studies on mice (HU et al., 2002). Bevacizumab (Avastin) is a recombinant humanized 
monoclonal antibody against VEGF, which has shown activity in ovarian cancer. 
Bevacizumab was given as a single agent to the women with recurrent ovarian or primary 
peritoneal cancer. 21% of women responded to therapy and 40% of patients had 
progression-free survival for 6 months and more (BURGER et al., 2005). However, a 
serious adverse effect (bowel perforation) has been reported due to use of Bevacizumab 
(HEINZERLING and HUERTA, 2006). 
Replacing defective genes that cause malignant behaviour of cancer cell is another 
approach. One such target is TP53. Promising preclinical data from in vitro systems led to 
phase I trials, but this trial was closed after first analysis due to the lack of any signs of 
efficacy (ZEIMET and MARTH, 2003). One of the possible problems is the presence of 
adenovirus-neutralizing antibodies in EOC ascites. Another study demonstrated that 
adenoviral transduction of primary ovarian cancer samples was abolished by autologous 
ascitic fluids (INGRAM et al., 2010). 
It is now recognized that in addition to genetic alterations, epigenetic mechanisms, such as 
DNA methylation, histone modifications and nucleosome remodeling, play an important 
role in the development and progression of ovarian cancer by modulating chromatin 
structure, and gene and miRNA expression. Furthermore, epigenetic alterations have been 
recognized as useful tools for the development of novel biomarkers for diagnosis, 
prognosis, therapeutic prediction and monitoring of diseases. Moreover, new epigenetic 
therapies, such as DNA methyltransferase inhibitors and histone deacetylase inhibitors, 
27 
have been found to be a potential therapeutic option for ovarian cancer, especially when 
used in combination with other agents (MARADEO and CAIRNS, 2011; MALDONADO 
andHOQUE, 2010). 
3. TRAIL as a promising agent for cancer treatment 
Tumor necrosis factor (TNF)-related apoptosis inducing ligand (TRAIL) is a member of the 
TNF superfamily. Because of its unique ability to trigger apoptosis (programmed cell 
death) in cancer cells and spare normal cells, TRAIL is a promising agent for cancer 
therapy. Deregulated apoptosis not only plays a key role in the pathogenesis and 
progression of cancer, but also leads to resistance to chemo and radiotherapy. Chemo and 
radiotherapy works effectively in killing some cancer cells through the intrinsic apoptotic 
pathway engaged by activation of p53 in response to DNA damage, but many tumors in 
which p53 is mutated or deleted are less sensitive to chemo or radiotherapy (LOWE et al., 
1994). In addition, the chemo or radiotherapy induces apoptosis in both cancer and normal 
cells and therefore possesses severe toxic side effects. 
Members of TNF family including Fas ligand, TNF and TRAIL have been identified as 
important targets for cancer biological therapy (ASHKENAZI, 2002). Administration of 
Fas Ligand or TNF can induce apoptosis in different cancer cells but cause severe toxicity 
to liver, limiting their application in the clinic (OGASAWARA et al., 1993; DUIKER et al, 
2006). TRAIL appears as a promising cancer therapeutic agent and induces apoptosis in 
wide variety of tumor cells without causing toxicity to normal cells (ASHKENAZI et al., 
1999). Importantly, TRAIL triggers apoptosis in cancer cells, regardless of p53 status, and 
therefore is an attractive agent especially for cancer cells in which p53 function has been 
inactivated, because it helps to overcome resistance to chemo and radiotherapy. 
3.1 TRAIL and its receptors 
Cells of immune system such as natural killers, T cells, macrophages and dendritic cells 
express TRAIL. TRAIL is inserted in the cell membrane with its C-terminal domain 
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exposed and has molecular weight of 33 kDa. It can be processed by cysteine proteases to 
produce soluble TRAIL of 20 kDa and both forms can trigger apoptosis by interacting with 
TRAIL receptors present in target cells. Five receptors that bind TRAIL have been 
identified so far (Figure 8). Only two of them, death receptor 4 (DR4) or TRAIL-R1 and 
DR5 or TRAIL-R2 are able to transmit an apoptotic signal (SHERIDAN et al, 1997). Two 
additional so called decoy receptors DcRl or TRAIL-R3 and DcR2 or TRAIL-R4 are 
incapable of transmitting an apoptotic signal (DEGLI-ESPOSTI et al, 1997). DR4 and 
DR5 contain death domains (DD) in their intracellular portion. DcRl lacks DD and instead 
possesses a glycosylphosphatidylinositol (GPI) anchor. DcR2 has a truncated DD. TRAIL 
also binds a soluble receptor called osteoprotegerin (OPG), which is involved in regulation 
of bone formation, but it has low affinity to TRAIL (TRUNEH et al, 2000). The selective 
killing of tumor cells by TRAIL has been explained by higher level of DR4 and DR5 
expression in tumor cells and relative high level of decoy receptors in normal cells (PAN et 
al, 1997). 
Human TRAIL/TRAIL receptors 
DcRl 
Figure 8. TRAIL and its receptors (WANG, 2008). There are 2 pro-apoptotic TRAIL 
receptors (DR4 and DR5) and three anti-apoptotic receptors (DcRl, DcR2 and OPG). 
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3.2 The physiological role of TRAIL and its receptors 
TRAIL-TRAIL receptor pathway regulates different physiological processes such as 
haematopoiesis (SECCHIERO and ZAULI, 2008), T-cell activation and survival 
(JANSSEN et al., 2005), and has been involved in many pathophysiological conditions 
including asthma, autoimmune diseases, diabetes, inflammation and excessive host immune 
responses in bacterial meningitis. TRAIL contributes to the host immunosurveillance 
against primary tumor development and metastasis by boosting the host responses to the 
tumor and somehow changing the tumor microenvironment for enhanced antigen 
presentation and tissue infiltration (JOHNSTONE et al., 2008). 
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3.3 Apoptotic TRAIL signaling 
There are two main apoptotic pathways to initiate the programmed cell death including 
extrinsic pathway and intrinsic pathway, and both are triggered depending on the different 
stimuli (Figure 9). 
-2/BeW 
mitochondrial loop 
amplification 
Smac/Diablo 
cytochrome C *8 
apoptosome 
Apoptosis •* 
Figure 9. Apoptotic TRAIL signalling. Binding of TRAIL to death receptors (DR4, DR5) 
leads to a Bid-cleavage-dependent mitochondrial amplification step. Translocation of tBid 
to the mitochondria promotes the assembly of Bax-Bak oligomers and mitochondria outer 
membrane permeability changes. Cytochrome c is released into cytosol resulting in 
apoptosome assembly. Active caspase-9 then propagates a proteolytic cascade of effector 
caspases activation that leads to morphological hallmarks of apoptosis. 
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Extrinsic pathway triggers apoptosis when TRAIL binds to DR4 or DR5 death receptors. 
The trimerized receptors recruit the adaptor protein FADD (Fas-associated protein with 
death domain) that simultaneously binds the inactive pro-form of caspase-8 or caspase-10 
via a shared death effector domain (DED) leading to formation of death inducing signaling 
complex (DISC). At the DISC pro-caspases are autoactivated by proteolysis. Activated 
caspase-8 or 10 then cleaves and directly activates the effector caspases (caspases-3,-6,-7) 
leading to the execution of apoptosis. FLIP (FLICE-inhibitory protein) has structural 
homology to pro-caspase-8, but lacks protease activity. Two splice variants of FLIP (long 
and short forms) were identified in human cells. This structure allows FLIP to bind to the 
DISC, thereby inhibiting the processing and activation of the initiator caspase-8 (Figure 9). 
The intrinsic pathway is usually triggered in response to DNA damage, hypoxia or 
oncogene overexpression. As a sensor of cellular stress p53 is critical initiator for the 
intrinsic pathway. This pathway involves the activation of pro-apoptotic Bcl-2 family 
members Bax and Bak that form pores in the outer mitochondrial membrane causing the 
release of pro-apoptogenic factors such as cytochrome c and Smac/Diablo (second 
mitochondria-derived activator of caspase/direct IAP binding protein with low pi). The 
release of cytochrome c leads to the formation of the apoptosome formed by released 
cytochrome c, APAF1 (apoptotic protease activating factor-1) and the inactive initiator 
caspase pro-caspase-9. Within apoptosome caspase-9 gets activated and it cleaves 
downstream effector caspases, leading to the apoptosis (Figure 9). 
The apoptotic self-destruction machinery is tightly controlled. Various proteins regulate the 
apoptotic process at different levels. IAPs (inhibitor of apoptosis proteins) can bind to and 
inhibit caspases. IAPs are inhibited by Smac/Diablo, which is released from mitochondria 
along with cytochrome c during apoptosis and it displaces IAPs from caspases (Figure 9). 
But the most important regulators of apoptosis at the mitochondrial level are apoptotic 
proteins that belong to the Bcl-2 family which control permeabilization of the outer 
mitochondrial membrane and release of cytochrome c and Smac/Diablo (BRUNELLE, 
2009). Once activated, caspase-8 cleaves pro-apoptotic Bcl-2 family member protein Bid 
and active truncated Bid (tBid) interacts with pro-apoptotic Bax/Bak. This interaction leads 
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to the increased release of cytochrome c from mitochondria. Bid activation provides a 
connection between extrinsic and intrinsic pathways called the mitochondrial bop 
amplification (Figure 9). 
In so called type I cells, activation of caspase-8 is sufficient to directly activate the 
downstream effector caspases leading to the apoptosis. The extrinsic pathway in type I cells 
is independent of mitochondria and could not be blocked by Bcl-2, whereas in type II cells 
such as ovarian cancer cells, the amount of caspase-8 or -10 is not enough to trigger the 
activation of effector caspases and apoptosis is initiated through the mitochondrial loop 
amplification (OZOREN and EL-DEIRY, 2002). 
3.3.1 Members of the Bcl-2 family 
It has been well established that Bcl-2 family proteins are involved in regulating apoptosis 
by controlling mitochondrial membrane permeability. Several studies have demonstrated 
that these proteins can interact with each other and these interactions can neutralize their 
pro- or anti-apoptotic functions. The balance between anti- and pro-apoptotic members of 
Bcl-2 family dictates the fate of cell survival or death. The Bcl-2 family can be divided into 
pro-apoptotic and anti-apoptotic proteins. These proteins contain one or more Bcl-2 
homology domains (BH), which share sequence homology (BRUNELLE and LETAI, 
2009; CORY et al., 2003; DANIAL and KORSMEYER, 2004). Most anti-apoptotic 
proteins contain BH domains 1-4 like Bcl-2, Bcl-XL, Bcl-w, Boo/Diva, and Mcl-1 (Figure 
10). 
Pro-apoptotic proteins can be divided into 2 groups according to their function and the 
number of BH domains possessed. BH domains 1-3 containing proteins are known as 
multidomain pro-apoptotic or effector proteins such as Bax, Bak, and Bok (Figure 10). 
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Figure 10. Members of Bcl^2 family (ER et al, 2006). Representation of all known 
mammalian Bcl-2 family members. Bcl-2 homology regions 1-4 (BH1-4) are indicated. TM 
indicates the transmembrane region that mediates localization to intracellular membranes. 
Ha5-Ha6 overlapping region containing BH1 domain corresponds to the pore-forming 
region. The BH3 domain in the pro-apoptotic members is a ligand for the hydrophobic 
pocket formed by the BH1-BH3 domains of the anti-apoptotic members. 
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The remaining pro-apoptotic proteins contain only BH3 domain and called BH3-only 
proteins like Bik, Bid, Bad, Bim, Bmf, Noxa, Puma, Blk and others. Most of these proteins 
contain a C-terminal hydrophobic a-helix, which is a potential transmembrane domain 
involved in their localization to the membranes of organelles such as the mitochondria, the 
ER and the nucleus. These proteins can form homo-dimers and/or hetero-dimers (ER et al., 
2006; OLTVAI et al., 1993; YANG et al., 1993), essentially through the interaction of their 
BH3 domain (CHITTENDEN et al., 1995). 
The BH4 domain of anti-apoptotic proteins is implicated in the control of their anti-death 
functions (SATTLER et al., 1997; HUANG et al, 1998). The molecular surface of the 
multidomain anti-apoptotic proteins contains BH3 binding grooves, which can 
accommodate BH3 domains from the pro-apoptotic members, resulting in highly variable 
affinities for each specific pair of interactions (LEVINE et al., 2008). 
Multidomain pro-apoptotic proteins Bax and Bak can form homo-dimers and hetero-dimers 
with BH3-only proteins such as Bid which induces their pro-apoptotic function. Bax and 
Bak can also form hetero-dimeric interactions with anti-apoptotic proteins such as Bcl-2. 
The a-helical conformation of anti-apoptotic Bcl-2 inserts into the hydrophobic groove of 
pro-survival Bax or Bak, thereby neutralizing the activity of multidomain pro-apoptotic 
proteins Bax and Bak to promote apoptosis (VAN DELFT and HUANG, 2006; LIU et al., 
2003; SATTLER et al., 1997; PETROS et al., 2000). 
Anti-apoptotic proteins can form homo-dimers and also hetero-dimers with pro-apoptotic 
BH3-only proteins such as Bid or Bad and this interaction results in neutralizing of pro-
survival function of anti-apoptotic Bcl-2 proteins. Several quantitative studies have 
indicated that Bim, Puma, and tBid (the truncated form of Bid, activated by caspase-8) bind 
avidly to all pro-survival proteins. The others pro-apoptotic proteins associate only with 
certain anti-apoptotic Bcl-2 family members. For example, Noxa engaged only with Mcl-1 
and Al leads to neutralization of the anti-apoptotic function of Mcl-1 and Al. Bad engaged 
only Bcl-2, Bcl-XL, and Bcl-w also neutralizing their function (ADAMS and CORY, 2007; 
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CHEN et al, 2005). These findings indicate that efficient apoptosis requires neutralization 
of multiple pro-survival proteins. 
The principle site of action of apoptosis regulation by Bcl-2-like proteins is the 
mitochondrial membrane. Anti-apoptotic proteins (Bcl-2, Bcl-XL, Bcl-w, and Mcl-1) 
mainly reside in mitochondria, protecting these organelles against mitochondrial membrane 
permeabilization (MMP). In addition, they can reside in other cellular compartments and 
hinder the movements of pro-apoptotic proteins to mitochondria. 
While pro-apoptotic Bak is normally associated with the outer mitochondrial membrane, 
Bax resides in the cytosol of healthy cells. Bax and Bak are the two principal proteins 
required for MMP. MMP result from conformational change of Bax and Bak and their full 
insertion into mitochondrial membranes as homo-oligomerized multimers. It leads to the 
formation of giant protein-permeable pores in the membranes leading to the release of the 
contents of the mitochondrial intermembrane space, including cytochrome c and 
Smac/Diablo into the cytosol that drives caspase activation and apoptosis (PALGLIARI et 
al, 2005; KROEMER et al, 2007). 
Given the lethal consequences of Bax and Bak activation, knowing how their activation is 
controlled is the key to understanding how a cell makes the decision to undergo apoptosis. 
Two models of Bax and Bak activation exist: the indirect and direct models (Figure 11). 
In direct activation model, a subgroup of BH3-only proteins, termed activators, are 
proposed to bind directly to Bax and Bak to promote their activation (KUWANA et al, 
2005). The remaining BH3-only proteins, termed as sensitizers, function by binding to the 
pro-survival proteins and freeing any bound Bim or tBid to directly activate Bax and Bak 
(ADAMS et al., 2007; CHEN et al, 2005). 
The indirect activation model proposes that all BH3-only proteins function solely by 
binding to their pro-survival relatives, thereby preventing those guardians of cell survival 
from inhibiting Bax and Bak (WILLIS et al, 2005; UREN et al, 2005). Several recent 
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findings strongly challenge the indirect activation model (WEI et al, 2000; CARTRON et 
al, 2004; REN et al, 2010). 
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Figure 11. Models for Bax/Bak activation by BH3-only proteins (VAN DELFT and 
HUANG, 2006). (A) Direct activation model. BH3-only proteins can be divided into two 
groups: "sensitizers" or "derepressors" (e.g. Bad) that bind only to pro-survival proteins 
and "activators" (e.g. Bim) that can also directly engage Bax and Bak. 
"Sensitizers/derepressors" induce apoptosis by displacing "activators" from pro-survival 
proteins, and "activators" then proceed to trigger Bax/Bak activation. (B) Pro-survival 
neutralization model. Pro-survival proteins inhibit Bax and Bak, perhaps through direct 
interaction. BH3-only proteins induce apoptosis by neutralizing pro-survival molecules and 
Bax/Bak activation occurs spontaneously in the absence of pro-survival activity. 
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3.4 Additional signal transduction pathways activated by TRAIL 
A number of studies show that TRAIL is also able to trigger non-apoptotic pathways (LIN 
et ai, 2000). Engagement of TRAIL receptors can lead to formation of a secondary 
signaling complex, probably after DISC assembly. This complex is formed by a part or all 
following proteins:.FADD, active caspase-8, receptor interacting protein 1 (RIP1), TNF 
receptor associated protein (TRAF-2) (Figure 12). 
Figure 12. Alternative TRAIL signaling (WANG, 2008). The secondary signaling 
complex leads to the activation of NFkB and JNK and increased expression of anti-
apoptotic or proliferation stimulatory proteins. The balance between pro- and anti-apoptotic 
signals varies between tumor cell types. 
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RIPl links TRAIL receptor to stimulation of nuclear factor-kB (NFkB) activation, which in 
turn transactivates anti-apoptotic proteins Mcl-1, IAPs, Bcl-XL and c-FLIP leading to the 
inhibition of apoptosis (RICCI et al, 2007). Mcl-1 can interact with tBid thereby 
preventing tBid-Bax/Bak interactions and blocks apoptosis (CLOHESSY, 2006). Recently 
it was demonstrated that Myc oncogene decreases the expression of Mcl-1 and IAPs by 
blocking TRAIL mediated NFkB activation (WANG, 2008; RICCI et al, 2007). Myc also 
directly transactivates DR5 or suppresses the transcription of c-FLIP, therefore enhancing 
TRAIL-induced apoptosis (Figure 12). 
TRAF2 leads to the JNK activation which promotes activation of pro-apoptotic protein Bim 
and results in apoptosis through the intrinsic mitochondrial pathway (CORAZZA et al, 
2006). 
TRAIL can also activate p38 mitogen-activated protein kinase (MAPK) pathway 
(MASTERS et al, 1996) and anti-apoptotic PBK/Akt pathway (SECCHIERO et al, 2003). 
Conflicting reports suggest that ERK, JNK or p38 signaling can either suppress or enhance 
the apoptotic efficacy of TRAIL (SECCHIERO et al, 2003; Lee et al, 2006; MUCHA et 
al, 2009; WANG et al, 2009; SHENOY et al, 2009). 
There is evidence that signal transduction mediated by TRAIL death receptors can be 
regulated by the localization of these proteins to cholesterol- and sphingolipid-rich lipid 
rafts within the plasma membrane (MUPPIDI and SIEGEL, 2004). Recently it was shown 
that ligation of DR4 and DR5 localized to lipid rafts induced a pro-apoptotic signal 
mediated by caspase-8 activation following DISC formation, but TRAIL receptors not 
associated with lipid rafts mediate the activation of NFkB, ERK1 and ERK2 (SONG et al, 
2007). 
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3.5 TRAIL receptor targeting agents 
Recombinant soluble TRAIL and agonist antibodies targeting TRAIL receptors have been 
used to induce TRAIL-mediated apoptosis in tumor cells, with each approach having their 
own advantages and drawbacks. 
In preclinical models, recombinant soluble TRAIL has demonstrated impressive anticancer 
activity. Importantly, no systemic toxicity was observed (WALCZAK et al., 1999). The 
first form of recombinant TRAIL that has been taken into the clinic is AMG-951. Due to 
significant tumor penetration it possesses high anti-tumor activity in vivo (KELLEY and 
ASHKENAZI, 2004). Recombinant TRAIL may bind to all five TRAIL receptors, which 
means that it can activate pro-survival pathways in tumor cells which can create resistance 
to TRAIL-induced apoptosis. To avoid this unwanted effect, agonistic monoclonal 
antibodies (mAbs) that only target DR4 and DR5 were created. Some of them are 
Mapatumumab (anti-DR4), Lexatumumab (anti-DR5), and Apomab (anti-DR5). An 
advantage of mAbs compared to soluble TRAIL is that they have high affinity to their 
targets, thus limiting non-specific binding to decoy receptors or OPG. In addition, mAbs 
have a much longer half-life (around 15 days) than recombinant TRAIL (30 min) making 
them easier to dose and administer (DUIKER et al., 2006). Moreover, mAbs can also 
recruit immune cells to the tumor site thus providing an additional means to antitumor 
activity (TAKEDA et al., 2004). Interestingly, it has been demonstrated that DR5 selective 
variants of TRAIL were more potent than wild type TRAIL to trigger apoptosis in ovarian 
cancer cells (VAN DER SLOOT et al., 2006). 
Finally, gene therapeutic approaches with TRAIL-expressing adenoviral vectors are also 
being explored. Efficient tumor cell killing by adenoviral-expressed TRAIL has been 
demonstrated in several tumor cell lines and mice (ABOU EL HASSAN et al., 2004; 
ZHANG et al., 2005). However, this type of treatment had limitations, such as problems 
related to viral delivery and poor cell infection efficiencies. 
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3.6 TRAIL resistance 
Despite promising results, studies have shown that number of cancer cells are resistant to 
TRAIL. TRAIL resistance has been reported in approximately 50 % of tested tumor cell 
lines reducing the expectations of monotherapy in the clinic (LEBLANC and 
ASHKENAZI, 2003). 
Various mechanisms are used by tumors to escape apoptosis induction, but deregulation of 
a unique pathway for resistance to TRAIL has not been identified so far. Susceptibility to 
TRAIL-induced apoptosis can be regulated at several levels in the apoptotic signaling 
pathway. Some of the commonly known resistance mechanisms have been described 
(Figure 13). 
It has been reported that lack of expression of DR4 due to epigenic silencing correlated 
with resistance to TRAIL-induced apoptosis in ovarian cancer cells (HORAK et al., 2005). 
Aside from the surface expression, post-translational modifications of the death receptors 
can reduce their ability to transduce TRAIL signal. O-glycosylation promotes ligand-
stimulated clustering of DR4 and DR5, which mediates recruitment of caspase-8 and 
apoptosis activation (WAGNER et al., 2007). S-palmitoylation of DR4 has also been 
identified as a pre-requisite for its localization to lipid rafts as well as for its ability to 
provide TRAIL-induced signalization (ROSSIN et al., 2009). 
Sensitivity to TRAIL can depend on ratio of TRAIL-decoy to death receptors. Decoy 
receptors can inhibit TRAIL-mediated apoptosis by competing with DR4 and DR5 for 
binding (MERINO et al., 2006). Also, mutated DR5 can similarly compete for ligand 
binding by acquiring a decoy receptor function (BIN et al., 2007). 
Resistance to TRAIL has also been correlated with high levels of c-FLIP that inhibits 
activation of caspase-8 at the DISC in several cancer types including breast, lung, colon 
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and ovarian cancer (GUSEVA et al, 2008; WANG et al, 2008; DOLCET et al., 2005; 
TOMEK et al., 2004; LANE et al, 2007). 
The ratio of pro-versus-anti-apoptotic Bcl-2 members is crucial for induction of intrinsic 
pathway of apoptosis. Resistance to TRAIL has been associated with increased levels of 
anti-apoptotic Bcl-XL (SONG et al, 2007), Mcl-1 (WANG et al, 2008; TANIAI et al, 
2004) and Bcl-2 (ZHANG and FANG, 2005) and decreased expression or mutations of pro-
apoptotic members such as Bax, Bak and Bid (RAVI and BEDI, 2002; JONG et al., 2004; 
VAN GEELEN, 2004; KANDASAMY et al., 2003; CHEN et al., 2001). 
High LAPs expression has been indicated as another mechanism of TRAIL resistance in 
different types of cancer, including ovarian cancer (CHAWLA-SARKAR et al., 2004; LEE 
et al., 2006; LIPPA et al., 2007). 
The pro-survival PI3K/Akt pathway has been shown to have negative impact on TRAIL-
induced apoptosis through its ability to increase the expression of anti-apoptotic proteins 
such as c-FLIP (PANNER et al., 2005), XIAP (SHRADER et al., 2007) and Bcl-2 (CHEN 
et al, 2001). .A number of studies have demonstrated that tumor cells with activating 
somatic mutations in PI3K are relatively resistant to apoptosis triggered by TRAIL or 
chemotherapy (ZHANG et al., 2009; CAMPBELL et al, 2004; YUAN et al, 2000). 
TRAIL-resistant ovarian carcinomas have been shown to have increased activation of 
PI3K/Akt pathway (ALTOMARE et al, 2004). 
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Figure 13. Mechanisms of resistance to TRAIL (MELLIER et al, 2010). Resistance 
arises from deficiencies at different levels of the TRAIL signaling pathway: at the receptors 
level (expression, localization, mutation, competition, and endocytosis/transport), at the 
DISC level (caspase-8, c-FLIP) or at the level of the mitochondrial apoptotic pathway 
(regulation of Bcl-2 family members, Smac/DIABLO, IAPs). 
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3.7 Resistance to TRAIL-induced apoptosis among ovarian cancer cells 
Previous studies have demonstrated that ovarian cancer cell lines and primary ovarian 
tumor cells isolated from malignant EOC ascites displayed variable sensitivity to TRAIL. 
TRAIL-mediated apoptosis was deficient in nearly 50% of ovarian cancer cell lines and 
primary tumors (LANE et al., 2004; CUELLO et al., 2001). 
Resistance to TRAIL therapy can be subdivided into a three categories: acquired, de-novo 
and intrinsic resistance (Figure 14). We demonstrated that acquired (induced) resistance to 
TRAIL-induced apoptosis in human ovarian cancer cells is conferred by increased turnover 
of mature caspase-3 (LANE et al., 2006). 
We have also investigated the de-novo resistance by treating EOC cells with ascites and 
demonstrated that EOC ascites, which represent a unique form of tumor microenvironment 
(Figure 3), protect TRAIL-sensitive CaOV3 cells from TRAIL-induced apoptosis by 
activating the PI3K/Akt pathway (LANE et al., 2007). In addition, we established that the 
PI3K/Akt pathway is activated by ascites through the av($5 integrin-mediated focal 
adhesion kinase activation (LANE et al., 2010). 
Nearly 50 % of EOC cell lines are intrinsically resistant to TRAIL-induced apoptosis 
meaning that these cells do not respond to the therapy the first time introduced to TRAIL. 
The mechanisms of intrinsic resistance to TRAIL in EOC cells are largely unknown. Our 
laboratory has previously shown that TRAIL induces apoptosis in only limited number of 
ovarian cancer cell lines (only two out of seven cell lines tested). Primary ovarian 
carcinoma cells display variable sensitivity to TRAIL. The lack of response to TRAIL was 
associated with limited activation of the apoptotic cascade in cell lines resistant to TRAIL 
(LANE et al., 2004). 
Although there are a number of mechanisms that can be altered in EOC cells that lead to 
intrinsic resistance to TRAIL, the PI3K/Akt pro-survival pathway is of particular interest 
because it has been implicated as a major determinant of oncogenic transformation in 
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ovarian cancer. PI3K is up-regulated in 30 to 45% of ovarian cancer cell lines 
(SHAYESTEH et al, 1999; CAMPBELL et al., 2004), whereas about 70% of primary 
tumors show elevated Akt activity (ALTOMARE et al, 2004). 
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Figure 14. Resistance to TRAIL, a) Acquired (induced) resistance develops over the time 
from exposure to sub-lethal TRAIL concentration. This type of resistance is associated with 
occurrence of sequential genetic alterations in the cells that eventually result in therapy-
resistant phenotype (MEADS et al., 2009). b) De-novo is environment-mediated resistance, 
in which tumor cells are transiently protected from TRAIL-induced apoptosis. This form of 
resistance is rapidly induced by signaling events that are initiated by factors present in the 
tumor microenvironment (KASSIS et al., 2004). c) Intrinsic resistance: some tumor cells 
are inherently resistant even to high concentrations of TRAIL without previous exposure to 
the agent. 
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4. PI3K/Akt pathway 
4.1 PI3K/Akt pathway components and activation mechanisms 
Phospatidylinositol-3 kinases, PI3Ks belong to a lipid kinase family that are activated in 
response to binding of growth factors and cytokines to receptors with protein tyrosine 
kinase activity (RPTK) or receptors coupled with G proteins. Once activated, PI3K 
phosphorylate the membrane lipid PIP2 (phospatidylinositol (4, 5)-biphosphate) into PIP3 
(phospatidylinositol (3, 4, 5)-trisphosphate) (Figure 15). PIP3 is an important messenger 
that induces the activation of downstream target proteins through binding of their 
pleckstrin-homology (PH) domain that is found in many proteins, including the protein 
serine/threonin kinase 3-phosphoinositide-dependent kinase-1 (PDK-1) and the protein 
kinase B (PKB) also known as Akt. Akt interacts with PDP3 at the inner membrane where 
PDK-1 is located. PDK-1 activates Akt by phosphorylation (Figure 15). Activated Akt is 
translocated to various subcellular compartments, including the Golgi, endoplasmic 
reticulum, mitochondria and nucleus where it phosphorylates substrates or interacts with 
other molecules. 
PTEN (phosphatase and tensin homologue deleted on chromosome 10) is the lipid 
phosphatase that reduces PIP3 levels in cell. PTEN specifically catalyses the 
dephosporylation of the 3" phosphate of the inositol ring in PIP3, resulting in the 
biphosphate product PIP2 (PtdIns(4,5)P2). By this action, PTEN negatively regulated 
PI3K/Akt pathway (CANTLEY and NEEL, 1999). PTEN has been shown to be mutated in 
5 to 8% of ovarian carcinomas (KOLASA et al., 2006; MUTTER, 2001), but in 
endometrioid carcinomas PTEN mutations were found in 20-26%. Interestingly, low grade 
endometriod carcinomas show higher frequency of PTEN mutations (80%) suggesting that 
PTEN mutations may play a role in a development of low-grade endometrioid tumors 
(KOLASA et al., 2006). Despite the fact that PTEN mutations were found in less than 10% 
of ovarian carcinomas, PTEN protein inactivation has been found in 27% of ovarian 
carcinomas (KUROSE et al., 2001) suggesting that transcriptional silencing by epigenetic 
mechanisms may be yet an additional means of modifying PTEN activity. 
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Figure 15. Mechanisms of Akt activation by PI3K. PI3K is induced as a result of 
receptor binding and activation of receptor tyrosine kinase (RTK). PBK phosphorylates the 
membraine lipid PIP2 to PIP3. PTEN, the lipid phosphatase removes the phosphate from 
PIP3 and by this action blocks the receptor binding signal from propagating downstream. 
These downstream signals include a number of kinases that contain the pleckstrin 
homology (PH) domain such as PDK1 and Akt. 
4.2 Akt/PKB 
Akt was originally identified as the human homologue of the viral oncogene v-akt from 
transforming retrovirus AKT 8. Akt (PKB) is now classified as a family of kinases that has 
significant homology to protein kinase A (PKA) and protein kinase C (PKC). 
To date, three members of this Akt family have been isolated, named Akt l (PKBa), Akt2 
(PKBP) and Akt3 (PKBy) (Figure 16). Although they are the product of different genes, 
they are closely related to each other, with up to 80% of amino acid homology (FRESNO 
VARA et al, 2004). 
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Figure 16. Three human Akt/PKB isoforms (OSAKI et al, 2004). Each Akt isoform 
consists of three functional domains: an N-terminal PH domain for binding inositol 
phospholipids, a central kinase domain including Thr308 (Thr309 in Akt3), and a C-
terminal regulatory domain including Ser473 (Ser474 in Akt2, Ser472 in Akt3). The 
number of amino acid residues is shown under each box. 
All three mammalian Akt genes are widely expressed in various tissues (OSAKI et al., 
2004). Aktl activity frequently elevated in breast and prostate cancers (SUN et al, 2001). 
36% of ovarian tumors exhibit elevated Akt2 activity (YUAN et al., 2000; BELLACOSA 
et al., 1995). Akt3 has been shown to be upregulated in estrogen receptor-deficient breast 
cancer cells and melanomas (STAHL et al., 2004). Recent study demonstrated that Akt3 
expression is detectable in 93% of primary ovarian tumors and specifically elevated in 
20%. In this study different ovarian cancer cell lines that have been evaluated showed 
variable levels of expression of all 3 Akt isoforms (CRISTIANO etal., 2006). 
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4.3 Cellular processes regulated by Akt 
Akt plays an essential role in cell survival, growth, migration, proliferation, polarity, and 
metabolism (lipid and glucose), cell cycle progression, angiogenesis, and cell-renewal of 
stem cells (LIAO and HUNG, 2010). 
4.3.1 Direct modulation of apoptosis by Akt 
Akt inactivates by phosphorylation some pro-apoptotic factors: Bad, Bax, Bim and caspase-
9 (Figure 17). 
The pro-apoptotic Bad protein binds to anti-apoptotic Bcl-2 and Bcl-XL and blocks their 
anti-apoptotic functions. Activated Akt directly phosphorylates Bad on serine 136 (DATTA 
et al., 1997). This phosphorylation of Bad by Akt results in the dissociation from Bcl-2 and 
Bcl-XL and binding of Bad to adapter protein 14-3-3 which results in Bad degradation 
(Figure 17). 
When apoptotic signals are present, pro-apoptotic protein Bax is going through 
conformational changes which allow Bax to translocate to mitochondrial membrane and 
oligomerize to form large pores which allows release of cytochrome c and other pro-
apoptotic factors from mitochondria (YAMAGUCHI and WANG, 2001). Phosphorylation 
of Bax by Akt on serine 184 results in inhibition of conformational change and inability of 
Bax to translocate to mitochondria. It was shown that phosphorylated Bax heteromerizes 
with Bcl-2 family members of anti-apoptotic function, such as Bcl-XL (GARDAI et al., 
2004). 
Caspase-9 acts as an initiator of the apoptotic process as part of the apoptosome. Akt can 
also directly phosphorylate the human caspase-9 on serine 196, resulting in its inactivation 
(CARDONE et al., 1998). 
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The pro-apoptotic activity of Bim can be regulated by Akt. A recent study has demonstrated 
that Akt can inhibit Bim functions by phosphorylating Bim on serine 87 (QI et al., 2006). 
Activation of stress-activated protein kinase (SAPK) pathway triggers mitochondria-
dependent apoptosis in response to many types of stress. SAPK composed of two groups of 
kinases: JNK and p38 MAPK. Akt phosphorylates three kinases upstream of SAPK: ASK1 
(apoptosis signal-regulating kinase 1) on serine 83 (KIM et al, 2001), MLK3 (mixed 
lineage kinase 3) on serine 674 (BARTHWAL et al., 2003) and MKK4 (mitogen-activated 
protein kinase kinase 4) on serine 78 (PARK et al., 2002). Phosphorylation results in 
inactivation of these three proteins. 
The glycogen synthase kinase-3 (GSK-3) can phosphorylate the anti-apoptotic protein Mcl-
1 which leads to its ubiquitination and facilitates cytochrome c release and apoptosis 
(MAURER et al., 2006). GSK-3 is inactivated by Akt phosphorylation on serine 21 and 9 
(CROSS et al., 1995). Since Akt negatively regulates GSK-3 activation, it contributes to 
Mcl-1 stability and survival (Figure 17). 
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Figure 17. Direct modulation of apoptosis by Akt The Bcl-2 family of proteins may 
represent a critical checkpoint in the mitochondrial intrinsic pathway of apoptosis and its 
members control cytochrome c release to the cytosol. By phosphorylating the pro-apoptotic 
molecule Bad, Akt induces its association with 14-3-3 proteins in the cytosol and thus 
contributes to the inhibition of Bad cell death functions. Akt also phosphorylates another 
pro-apoptotic member of the Bcl-2 family, Bax. Phosphorylated Bax promotes 
heterodimerization with anti-apoptotic Mcl-1 and Bcl-XL, leading to abrogation of Bax 
activity. Moreover, Akt has been found to phosphorylate and negatively regulate the Mcl-1 
inhibitor, GSK-3. At the post-mitochondrial level, Akt may phosphorylate and inactivate 
caspase-9, resulting in the abolition of the caspase cascade. Akt also can abrogate activation 
of stress-activated protein kinase (SAPK) pathway. 
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4.3.2 Indirect modulation of apoptosis by Akt 
The mediation of apoptosis execution by Akt also involves changes in the transcription 
program. Akt regulates transcription of factors responsible for the expression of pro- or 
anti-apoptotic molecules (Figure 18). 
Figure 18. Indirect modulation of apoptosis by Akt (PARCELLIER et al, 2008). 
PKB/Akt phosphoryiates and inhibits FoxO and also activates CREB after its 
phosphorylation, resulting in the downregulation of pro-apoptotic and upregulation of anti-
apoptotic Bcl-2 family members. Moreover, by phosphorylating and activating IKK, 
PKB/Akt induces I-icBa phosphorylation. Thus, NF-KB is activated and induces expression 
of Bcl-2 anti-apoptotic proteins. On the other hand, phosphorylation by PKB/Akt stabilizes 
Mdm2 and increases Mdm2 ubiquitin ligase activity, leading to a decrease in p53 
transcriptional activity. 
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Forkhead family members: It has been shown that Akt is able to directly phosphorylate 
Forkhead protein (FoxO) and in this way it is responsible for their nuclear exclusion and 
inactivation (KOPS et al., 1999). FoxO target genes are important for inhibition of cell 
survival and the promotion of apoptosis. For example, FoxO proteins regulate expression of 
pro-apoptotic Bcl-2 family members such as Bim or Bcl-6 (BURGERING et al., 2003). 
Murine double minute 2 (Mdm2): Mdm2 is an E3 ubiquitin ligase that negatively controls 
intracellular levels of the tumour suppressor p53. p53 is a major regulator of cell death and 
induces apoptosis by upregulating pro-apoptotic proteins PUMA and NOXA (NAKANO 
and VOUSDEN., 2001; SHIBUE et al, 2003). It has been reported that Akt binds to and 
phosphorylates Mdm2, leading to its stabilization and allowing its nuclear import and 
increasing its ubiquitin ligase activity (GOTTLIEB et al., 2002). 
NF-KB: Control of the inflammatory response and apoptosis are closely linked to NF-KB 
activation. NF-KB translocates to the nucleus where it activates pro-survival genes (Figure 
12) including Bcl-XL, caspases inhibitors and c-Myb (BARKETT and GILMORE., 1999; 
LAUDER et al., 2001). NF-KB negatively regulated by its inhibitor I-KBa which is 
degraded by activation of I-KBa kinase (IKK). Akt has been shown to regulate IKK activity 
by phosphorylating IKK at the threonin 23 residue. This activates IKK, which then targets 
I-KBa for proteasomal degradation (OZES et al., 1999). 
Cyclic AMP-response element-binding protein (CREB): Akt phosphorylates CREB on 
Serl33, leading to CREB activation and the promotion of cell survival through stimulation 
of the expression of the anti-apoptotic Mcl-1 (WANG et al, 1999) and Bcl-2 
(PUGAZHENTHI et al., 2000). Finally, CREB phosphorylation and activation by Akt is 
also responsible for an increase in Akt expression, thus reinforcing Akt anti-apoptotic 
functions (REUSCH and KLEMM, 2002). 
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4.3.3 Regulation of cell growth and cell cycle progression by Akt 
Akt promotes cell cycle progression and cell growth by phosphorylating different targets: 
glycogen synthase kinase-3 (GSK-3), mammalian target of rapamycin (mTOR), cyclin-
dependent kinase inhibitors p21 and p27 (Figure 19). 
In addition to upregulation of Mcl-1 protein (Figure 17), GSK-3 inhibition by Akt also 
prevents the phosphorylation of the cytoplasmic signaling molecule fi-catenin by GSK-3, 
which prevents its degradation. (3-catenin translocates to the nucleus and induces expression 
of cyclin Dl, which induces cell cycle progression through the Gl/S phase (DIEHL et al, 
1998). 
Akt phosphorylates p21 and inhibits its antiproliferative effects by retaining it within the 
cytoplasm (ZHOU et al, 2001). A similar mechanism has been described for p27 (LIANG 
et al., 2002; SHIN et al, 2002). 
The mammalian target of rapamycin (mTOR) also known as mechanistic target of 
rapamycin is a serine/threonine protein kinase that regulates cell growth, cell motility, cell 
survival, protein synthesis. Activation of mTOR by Akt occurs through inactivation of the 
tuberous sclerosis complex (TSC) by phosphorylation. Unphosphorylated TSC complex 
blocks mTOR activation. This complex is disrupted by Akt-mediated phosphorylation. 
Thus, in the presence of mitogen stimulation of the PI3K/Akt pathway and sufficient 
nutrients, mTOR stimulates the translation of proteins such as cyclin Dl and c-myc 
required for the cell cycle progression from the G1 to the S phase (POTTER et al., 2002; 
MANNING et al, 2002; INOKI et al, 2002). 
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Figure 19. Regulation of cell cycle progression by Akt. Activated Akt promotes cell 
cycle progression through multiple mechanims, including direct phosphorylation of cyclin 
dependent kinase (CDK) inhibitors p21 and p27. Activation of mTOR by Akt stimulates 
the translation of proteins such as cyclin D1 and c-myc, both required for cell cycle 
progression from the G1 to the S phase. Cyclin D1 is further an indirect target of Akt 
through GSK-3-mediated transcription. 
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4.4 Inhibitors targeting PI3K/Akt pathway 
Given the importance of the PI3K/Akt pathway, new inhibitors targeting this pathway are 
being developed. One of them is Wortmannin fungal metabolite that has shown to have 
antitumor activity in vitro and in vivo studies (POWIS et al., 1994; SCHULTZ et al, 1995). 
But a disadvantage of Wortmannin is its stability in an aqueous environment. Wortmannin 
is soluble in organic solvents, which limits its use in clinical trials. Stable water-soluble 
conjugates of Wortmannin are being developed to improve its pharmacological 
characteristics. 
The flavonoid derivative, LY294002, is a competitive and reversible inhibitor of the ATP 
binding site of PI3K. Several studies have shown that LY294002 alone has antiproliferative 
and pro-apoptotic activities (CASAGRANDE et al., 1998). LY294002 has a very short 
half-life and is insoluble in aqueous solutions (HENNESSY et al., 2005). 
The macrolide rapamycin and its derivates inhibit mTOR. All rapamycins under clinical 
development have antiproliferative activity as single agents (MUTHUKKUMAR et al., 
1995; SEUFFERLEIN and ROZENGURT, 1996). 
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5. Hypothesis and objectives of the project 
Even though TRAIL represents a novel promising agent for the treatment of different types 
of cancer, resistance to this agent is common among EOC (LANE et ai, 2004). TRAIL is 
also known to induce survival and proliferation in TRAIL-resistant cancer cells 
(EHRHARDT et al, 2003; LEVINA et al., 2008). Understanding the mechanisms of 
resistance to TRAIL is essential in order to optimise the introduction of TRAIL into the 
clinic and to better understand if TRAIL treatment in patients that harbour tumor cells that 
are intrinsically resistant, shift the patient's treatment from beneficial to detrimental. 
Several studies have provided insights on the mechanisms of acquired and de-novo 
resistance to TRAIL. Our laboratory demonstrated that that EOC ascites protected TRAIL-
sensitive cells from TRAIL-induced apoptosis by activating Akt (LANE et al., 2007). In 
addition, we demonstrated that cell detachment decreased Akt activity and sensitized 
TRAIL-resistant EOC cells to TRAIL (LANE et al., 2007). But little is known about 
mechanisms of intrinsic resistance to TRAIL and the goal of this project was to better 
understand these mechanisms. 
Based on the data described above we hypothesized that intrinsic resistance to TRAIL in 
EOC cell lines is associated with Akt activation. To investigate this hypothesis we selected 
two TRAIL-sensitive cell lines (CaOV3 and OVCAR3) and two TRAIL-resistant 
(SKOV3ipl and COV2) cell lines (Figure 20). The basal level of activated 
(phosphorylated) Akt was significantly higher in TRAIL-resistant cell lines compare to 
TRAIL-sensitive. 
Our first objective was to demonstrate that PI3K/Akt activation in EOC cells correlates 
with TRAIL resistance by investigating: 1-Akt activation and sensitivity to TRAIL among 
EOC primary samples, 2- by investigating how Akt overexpression in TRAIL-sensitive cell 
lines and Akt downregulation in TRAIL-resistant cell lines will affect sensitivity of these 
cells to TRAIL. The second objective was to identify the mechanisms by which Akt 
contributes to TRAIL resistance in EOC cells. 
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Figure 20. Effect of TRAIL on EOC cells. In the presence of TRAIL (cells were treated 
with 25 ng/ml TRAIL for 24h), sensitive CaOV3 and OVCAR3 cells were rounded and 
floating in the medium, suggesting massive cell death, whereas resistant SKOV3ipl and 
COV2 cells form typical epithelial monolayer with only small proportion of rounded cells. 
RESUME DE L'ARTICLE 
L'inhibition de l'expression de Bid par Akt augmente la resistance a 1'apoptose 
induite par TRAIL dans les cellules de cancer ovarien. 
N Goncharenko-Khaider, D Lane, I Matte, C Rancourt and A Piche 
Departement de Microbiologic et Infectiologie, Faculte de Medecine, Universite de 
Sherbrooke, Sherbrooke, Canada 
La voie de PI3K/Akt est souvent activee dans les cellules cancereuses ovariennes (CEO), 
suggerant un role dans la pathogenese. De plus, nous avons montre precedemment que les 
ascites provenant de patientes avec cancer ovarien epithelial induisaient une activation 
d'Akt chez la lignee de cancer ovarien CaOV3 sensible au TRAIL, provoquant une 
inhibition de 1'apoptose mediee par TRAIL. Le but de l'etude presente est d'evaluer le role 
d'Akt dans la resistance intrinseque au TRAIL, ce qui est frequent dans les cellules de 
CEO. Nos resultats demontrent que l'activation d'Akt reduit la sensibilite au TRAIL des 
cellules de cancer ovarien. Les cellules resistantes au TRAIL, SKOV3ipl et COV2, ont ete 
sensibilisees a 1'apoptose induite par le TRAIL avec des inhibiteurs de PI3K ou d'Akt, 
meme si l'inhibition de la voie de signalisation PI3K/Akt n'interfere pas avec le 
recrutement et l'activation de la caspase-8 dans le complexe de signalisation induisant la 
mort. Reciproquement, la surexpression d'Aktl dans les cellules sensibles au TRAIL, 
augmente la resistance au TRAIL. Meme si le fait que l'activation de la caspase-8 induite 
par le TRAIL a ete observee a la fois dans les lignees sensibles et dans les lignees 
resistantes, le clivage de Bid n'est observe que dans les cellules sensibles ou dans les 
cellules SKOV3ipl traitees avec Pinhibiteur de PI3K, LY294002. Les cellules resistantes 
expriment des niveaux de Bid significativement plus faible que les cellules sensibles et 
l'activation de Bid regule negativement son expression. La depletion de Bid au moyen de 
siRNA dans les cellules sensibles OVCAR3 est associee avec une diminution de 1'apoptose 
mediee par TRAIL. Un blocage simultane de la voie d'Akt augmentait d'avantage 
1'apoptose induite par TRAIL. Done, Akt agit en amont de la mitochondrie et inhibe 
I'apoptose induite par TRAIL en diminuant les niveaux de la proteine Bid et possiblement 
en inhibant son clivage. 
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The inhibition of Bid expression by Akt leads to resistance to TRAIL-induced 
apoptosis in ovarian cancer cells 
N Goncharenko-Khaider, D Lane, I Matte, C Rancourt and A Piche 
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ABSTRACT 
Epithelial ovarian cancer (EOC) cells often show increased activity of the PI3K/Akt 
pathway. In addition, we have previously shown that EOC ascites induce Akt activation in 
the tumor necrosis factor-related apoptosis inducing ligand (TRAIL)-sensitive EOC cell 
line, CaOV3, leading to TRAIL-mediated apoptosis inhibition. In this study, we 
investigated the role of Akt in intrinsic resistance to TRAIL, which is common in EOC 
cells. We report that Akt activation reduces the sensitivity of EOC cells to TRAIL. TRAIL-
resistant SKOV3ipl and COV2 cells were sensitized to TRAIL-induced apoptosis by PI3K 
or Akt inhibitors although inhibition of PI3K/Akt signaling pathway did not interfere with 
the recruitment and processing of caspase-8 to the death-inducing signaling complex. 
Conversely, overexpression of Aktl in TRAIL-sensitive cells promoted resistance to 
TRAIL. Although the fact that TRAIL-induced caspase-8 activation was observed in both 
sensitive and resistant cell lines, Bid cleavage occurred only in sensitive cells or in 
SKOV3ipl cells treated with LY294002. Bid expression was low in resistant cells and Akt 
activation downregulated its expression. Depletion of Bid by siRNA in OVCAR3 cells was 
associated with a decrease in TRAIL-mediated apoptosis. Overexpression of Bid only in 
SKOV3ipl cells enhanced TRAIL-induced apoptosis. Simultaneous blockade of Akt 
pathway further increased TRAIL-induced apoptosis. Thus, Akt acts upstream of 
mitochondria and inhibits TRAIL-induced apoptosis by decreasing Bid protein levels and 
possibly inhibiting its cleavage. 
Oncogene (2010) 29, 5523-5536; doi:10.1038/onc.2010.288; published online 26 July 
2010. 
Keywords: death receptors; ovarian carcinoma; resistance; PI3K/Akt pathway; TRAIL; 
Bid 
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INTRODUCTION 
Resistance to chemotherapy is a major problem in epithelial ovarian cancer (EOC) 
treatment. Despite initial high response rate in patients with advanced EOC, most patients 
relapse with tumor that acquires resistance to chemotherapy (Yap et al, 2009). The tumor 
necrosis factor related-apoptosis-inducing ligand (TRAIL) holds great promise as an anti­
cancer therapy because of its selective apoptosis-inducing action on tumor cells vs. normal 
cells (Newsom-Davis et al., 2009). TRAIL-based therapies are now in phase I/II clinical 
trials (http://www.clinicaltrials.gov). TRAIL resistance in tumor cells, including EOC, may 
limit its therapeutic use (LeBlanc et al, 2002; Lane et al., 2004; Zhang and Fang, 2005). 
On binding to its receptors DR4 (TRAIL-Rl) and DR5 (TRAIL-R2) TRAIL induces the 
formation of the death-inducing signaling complex (DISC) by recruiting Fas-associated 
death domain. Fas-associated death domain through its death effector domain recruits pro-
caspases-8/10, which assemble into the DISC (Kischkel et al., 1995; Bodmer et al, 2000). 
When recruited to the DISC, pro-caspase-8 is activated through proteolytic cleavage, 
resulting in active caspase-8 that may directly cleave downstream effector caspases 
(caspase-3, -6 and -7) leading to apoptosis. Alternatively, caspase-8 cleaves the BH3 
domain-containing protein Bid, to generate a pro-apoptotic truncated form (tBid), which 
translocates to the mitochondrial membrane and triggers the intrinsic apoptosis pathway. 
Although there are a number of means by which the association between TRAIL 
signaling cascade and the apoptotic machinery could be altered in TRAIL-resistant EOC 
cells, the phosphatidylinositol-3-kinase PI3K/Akt pathway is of particular interest because 
it is an important determinant of oncogenic transformation in EOC. The PI3K/Akt pathway 
is activated in a significant number of EOC cells (-70%) because of amplification/ 
overexpression/mutation (Bast et al., 2009). Activation of the PI3K/Akt pathway was 
shown to have a role in protecting EOC cells from chemotherapy-induced apoptosis (Page 
et al, 2000; Hu et al, 2002; Yang et al, 2006). Drugs and death receptor ligands rely on 
activation of apoptotic signaling pathways to destroy tumor cells. Indeed, the resistance to 
chemotherapy is because of the failure of tumor cells to undergo apoptosis. As shown by us 
and others, death receptor-mediated apoptosis is deficient in nearly 50% of ovarian cancer 
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cell lines and primary tumors (Lane et ah, 2004). Consequently, to fully exploit the 
potential of TRAIL, the problem of TRAIL resistance in EOC cells must be first 
understood. 
Akt activation was shown to protect against TRAIL-induced apoptosis in several 
cell types, including melanomas and prostate, ovarian and non-small cell lung cancers 
(Chen et ah, 2001; Nesterov et ah, 2001; Kandasamy and Srivastava, 2002; Larribere et ah, 
2004; Kim and Lee, 2007; Lane et ah, 2007). However, there are conflicting reports about 
the mechanisms by which Akt exerts its protective effect. In non-small cell lung and 
prostate cancer, Akt activation inhibited TRAIL-induced apoptosis by interfering with Bid 
cleavage by means of an unknown mechanism (Chen et ah, 2001; Nesterov et ah, 2001; 
Kandasamy and Srivastava, 2002). Inhibition of PI3K or Akt completely blocked the anti-
apoptotic effect of stem cell factor on TRAIL-induced apoptosis in melanoma cells 
(Larribere et ah, 2004). FLIP did not appear to be involved but the precise mechanism was 
unclear. In TRAIL-sensitive EOC cells, inhibition of PI3K and Akt substantially inhibited 
the pro-survival effect of EOC ascites by a mechanism that involved upregulation of c-
FLIPs (Lane et ah, 2007). 
Previous studies have shown that EOC cell susceptibility to TRAIL cannot be 
explained by the levels of TRAIL receptors (Cuello et ah, 2001; Siervo-Sassi et ah, 2003; 
Lane et ah, 2004). TRAIL induces mitochondria-dependent apoptosis in EOC, a 
characteristic of the type II cells (Cuello et ah, 2004). Bid has a central role in type II cells 
by connecting the mitochondria pathway of apoptosis to the extrinsic pathway (Newsom-
Davis et ah, 2009). Akt regulates the activity of Bad, Bax and X-linked inhibitor of 
apoptosis (XIAP) to promote survival (Datta et ah, 1997; del Peso et ah, 1997; Kandel and 
Hay, 1999; Dan et ah, 2004). Akt may also upregulate the expression of anti-apoptotic 
proteins such as Bcl-2 (Du and Montminy, 1998). However, a recent study has shown that 
Akt activation does not affect the expression of Bcl-2, Bcl-XL and Bax (Lane et ah, 2007). 
Thus, the mechanisms by which Akt confers protection and its action on the mitochondrial 
pathway in TRAIL-induced apoptosis remains to be fully understood in EOC cells. 
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In this study, we have examined the role of Akt and the mechanism of intrinsic 
TRAIL resistance in ovarian cancer cells. We report for the first time that Akt activation 
inhibits TRAIL-induced apoptosis by decreasing Bid expression. Furthermore, Bid 
depletion by RNA interference led to a decrease of TRAIL-induced apoptosis. These results 
show that Akt acts upstream of the mitochondria at the Bid level to inhibit TRAIL-induced 
cell death in EOC cells. 
RESULTS 
TRAIL resistance is associated with Akt activation in EOC cells 
We have previously shown that ascites-mediated Akt activation protects CaOV3 cells 
against TRAIL-induced apoptosis (Lane et al., 2007). In addition, we showed that cell 
detachment decreased Akt activity and sensitized SKOV3ipl and COV2 EOC cells to 
TRAIL (Lane et al., 2008). These data suggest that Akt may be an important regulator of 
TRAIL-induced apoptosis. In this study, we investigated whether Akt is indeed a mediator 
of TRAIL resistance. For our studies, four EOC cell lines were used. The cell lines were 
subdivided into sensitive (<20% cell viability; CaOV3 and OVCAR3 cells) and resistant 
(80% cell viability; COV2 and SKOV3ipl cells) to TRAIL-induced cell death (Figure la). 
In sensitive cells, TRAIL treatment decreased the number of colonies by 10-fold whereas 
the number of colonies remained mostly unchanged in resistant cells (Figure lb). TRAIL-
induced apoptosis was significantly greater in sensitive cells when compared with COV2 
and SKOV3ipl cells as measured by oligosomal DNA fragmentation (Figure lc) and the 
percentage of hypodiploid cells (Figure Id). 
We examined the basal level of phospho-Akt in our panel of cell lines. As shown in 
Figure le, there was a positive correlation between high levels of Akt phosphorylation and 
resistance to TRAIL. Interestingly, however, there was no correlation between levels of c-
FLIPs or C-FLIPL proteins, which inhibit caspase-8 activation at the DISC (Kruger et al., 
2001; Panka et al., 2001; Panner et al., 2005), and the sensitivity of EOC cell lines to 
TRAIL-induced apoptosis. 
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Figure 1 Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) resistance 
correlates with Akt activation in ovarian cancer cells. Cell viability was assessed in four 
ovarian cancer cell lines by a short-term assay where cells were incubated with TRAIL 
(100 ng/ml) for 48 h and viability was assessed by XTT assay (a), and by a long-term assay 
where cells were treated with TRAIL (100 ng/ml) or left untreated (control) for 24 h and 
colonies were counted after 14 days (b). Apoptosis was measured by determining 
oligosomal DNA fragmentation (c) and the percentage of apoptosis (d) was measured as 
percentage of hypodiploid cells assessed by flow cytometry analysis during exposure to 
TRAIL (100 ng/ml) for 24 h. Data shown are means ± s.e.m. derived from three 
independent experiments, (e) Expression/phosphorylation of Akt, FLIPL and FLIPs were 
analyzed by western blotting with appropriate antibodies. Representative immunoblot from 
three independent experiments. *P<0.001. 
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Overexpression of Aktl inhibits TRAIL-induced apoptosis in CaOV3 cells 
We determined whether Aktl overexpression would exert a protective effect against 
TRAIL-induced apoptosis. CaOV3 cells overexpressing Aktl (CaOV3-Akt-l (wt)) or 
vector-transfected cells (CaOV3 (vector)) were validated by immunoblot (Figure 2a). Of 
note, the ectopic expression of Aktl did not affect the protein levels of FLIPL and FLIPs 
(data not shown). CaOV3-Akt-l (wt) cells were significantly (P<0.001) more resistant to 
TRAIL compared with CaOV3 (vector) cells as indicated by a dose-response curve (Figure 
2b) and colony formation after TRAIL exposure (20 ng/ml) (Figure 2c). However, the 
resistance of CaOV3-Akt-l (wt) cells can be overcome by higher concentrations of TRAIL 
(Figure 2b). We believe that this may be related to relatively low levels of pAkt in CaOV3-
Akt-1 (wt) cells despite high expression of total Akt. The level of cell death for CaOV3 
(vector) cells was comparable to that of the parental CaOV3 cells (data not shown). 
Oligosomal DNA fragmentation and the percentage of hypodiploid cells were used to 
measure apoptosis. Aktl overexpression decreased TRAIL-induced DNA fragmentation 
(Figure 2d) and the percentage of apoptosis (Figure 2e) to a level equal to untreated cells, 
suggesting that TRAIL-induced apoptosis is inhibited by expression/activation of Akt. 
Interestingly, despite showing resistance to TRAIL, CaOV3-Akt-l (wt) cells showed 
similar levels of caspase-8 activity to control CaOV3 (vector) cells after TRAIL treatment 
(Figure 2f). However, caspase-3 activity was significantly lower in Aktl-expressing 
CaOV3 cells as compared with control cells. These data suggest that Akt confers resistance 
to TRAIL-induced apoptosis by interfering downstream of caspase-8. 
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Figure 2 Overexpression/phosphorylation of Akt inhibits TRAIL-induced apoptosis in 
CaOV3 cells. TRAIL-sensitive CaOV3 cells were stably transfected with empty vector 
(CaV03 (vector)) or with Aktl-encoding construct (CaOV3-Akt-l (wt)). (a) After 
selection, cells were analyzed for Akt expression and phosphorylation by immunoblot. Cell 
viability was assessed by short-term XTT assay in the presence of increasing concentration 
of TRAIL (b) or by long-term assay where cells were left untreated or exposed to TRAIL 
(20 ng/ml) for 24 h. After 14 days colonies were counted (c). Apoptosis was measured by 
determining oligosomal DNA fragmentation (d) and the percentage of apoptosis (e) was 
measured as percentage of hypodiploid cells assessed by flow cytometry analysis during 
exposure to TRAIL (20 ng/ml) for 24 h. Data shown are means ± s.e.m. derived from three 
independent experiments. (I) Caspase-8 and caspase-3 activity were measured using 
fluorogenic substrates in CaOV3-vector and CaOV3-Akt-l wt cells treated with TRAIL (0 
to 10 ng/ml). Data shown are means ± s.e.m. derived from three independent experiments. 
*P<0.001. 
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PI3K and Akt inhibitors enhance TRAIL-induced apoptosis in resistant cells 
To further confirm the role of Akt, we assessed whether PI3K inhibitor LY294002 or Akt 
inhibitor blocked Akt activation and enhanced TRAIL-sensitivity in resistant cells. 
Treatment of SKOV3ipl and COV2 cells with LY294002 (5 (iM) for 60 min strongly 
blocked Akt phosphorylation (Figure 3a). Although we did not find any correlation 
between c-FLIPs or c-FLIPL protein levels and TRAIL sensitivity (Figure le), we assessed 
the effect of LY294002 on c-FLIPs or C-FLIPL expression to ensure that Akt activity does 
not affect their expression. Figure 3b shows no effect of PI3K inhibition on c-FLIPs or c-
FLIPL protein levels in SKOV3ipl cells. Similarly, the levels of pAkt and total Akt were 
not affected by TRAIL in SKOV3ipl cells (Figure 3c). Pre-incubation of SKOV3ipl or 
COV2 cells with LY294002 (5 (iM) or Akt inhibitor (10 ^M) sensitized these cells to 
TRAIL-induced apoptosis as shown by increased oligosomal DNA fragmentation (Figure 
3d) and increased rounded dead cells (Figure 3e) compared with controls. 
Akt activation in human primary samples of EOC correlated with decreased TRAIL 
sensitivity 
To determine whether Akt activation is correlated with decreased TRAIL sensitivity in 
clinical samples of EOC, we obtained primary samples of tumor cells from women having 
serous ovarian carcinoma. The sensitivity of primary ovarian tumors cells to TRAIL was 
determined by XTT assay as described previously (Lane et al., 2004), and expressed as 
IC50. The relative expression of pAkt in primary samples was assessed by western blotting, 
measured by densitometric quantification and expressed as fold increased relative to pAkt 
levels in CaOV3 cells. pAkt levels in primary tumor samples correlated well and positively 
with increased TRAIL IC50, indicating that Akt activation confers resistance to TRAIL in 
vivo (n=12, Pearson's r=0.950; P<0.0001). 
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Figure 3 Inhibition of the PI3K/Akt pathway sensitizes ovarian cancer cells to TRAIL-
induced apoptosis. TRAIL-resistant SKOV3ipl and COV2 cells were incubated with 
LY294002 (5 nM) for 60 min, after which immunoblot analysis was performed to 
determine (a) Akt phosphorylation and (b) FLIPL and FLIPs expression, (c) SKOV3ipl 
cells were treated with TRAIL (100 ng/ml) and Akt phosphorylation was monitored for up 
to 5 h. Resistant cells were incubated with LY294002 (5 (iM) or Akt inhibitor (10 nM) for 
60 min, after which TRAIL (100 ng/ml) was added for 48 h. Apoptosis was determined by 
measuring oligosomal DNA fragmentation (d) and visualizing cells by optical microscopy 
(e). Data shown are representative of three independent experiments. Values are the means 
± s.e.m. *P<0.001. 
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TRAIL resistance is downstream of caspase-8 but upstream of mitochondria 
Analysis of caspase activation indicated that the pro-caspases were processed and cleaved 
fragments of caspase-8 (p43/41, pi8) and caspase-9 (p35) were generated in TRAIL-
sensitive OVCAR3 cells (Figure 4a). The generation of active caspase-8 and caspase-3 
fragments was confirmed by measuring the cleavage of caspase-8 and caspase-3 substrates 
in OVCAR3 cells (Figure 4b). In contrast, only partially processed caspase-8 p43/41 
fragments were detected in SKOV3ipl and neither caspase-8 nor caspase-9 mature 
fragments were detected. The measurement of caspase-8 activity however, showed 
substantial caspase-8 substrate cleavage in SKOV3ipl cells although to a lesser extend 
relative to OVCAR3 cells (Figure 4b). This indicated that caspase-8 is activated in 
SKOV3ipl but probably at a level which is too low to be detected by an immunoblot. 
Caspase-3 activity was not, however, detected in SKOV3ipl cells (Figure 4b). As binding 
of TRAIL to its receptors causes recruitment of pro-caspase-8 at part of the DISC, resulting 
in activation of caspase-8, we immunoprecipitated the DISC in cells treated with FLAG-
tagged TRAIL. As shown in Figure 4c, pro-caspase-8 was recruited and cleaved at the 
DISC in a time-dependent manner in both sensitive and resistant cells. Of note, recruitment 
and processing of pro-caspase-8 at the DISC was not affected by LY294002 (Figure 4d). 
Similarly, caspase-8 activity in total cell lysate of SKOV3ipl cells was not inhibited by 
LY294002 (Figure 4e) indicating that Akt blockade occurs downstream of caspase-8. 
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Figure 4 Blockade of the TRAIL signaling cascade is located downstream of caspase-8 in 
resistant cells. (a) Caspase cleavage during TRAIL treatment (100 ng/ml) was assessed by 
immunoblot analysis after 24 h in TRAIL-sensitive CaOV3 and TRAIL-resistant 
SKOV3ipl. NS, nonspecific band, (b) Caspase-8 and caspase-3 activity in sensitive and 
resistant epithelial ovarian cancer (EOC cells) were measured by the cleavage of 
fluorogenic substrate IETD-AFC and DEDV-AFC after TRAIL treatment (100 ng/ml) for 
24 h. (c) TRAIL receptors were immunoprecipitated using Flag-tagged recombinant 
TRAIL and anti-Flag M2 antibody at various times after TRAIL treatment. Co-
immunoprecipitated DR5 (doublet) and caspase-8 (pro-caspase-8, p55 and cleavage 
fragments, p43/41) were revealed by immunoblotting. (d) SKOV3ipl cells were incubated 
for 1 h with LY294002 (5 ^M), after which caspase-8 was co-immunoprecipitated as 
described above following Flag-tagged TRAIL treatment for 1 h. (e) Caspase-8 activity was 
measured in SKOV3ipl cells treated with LY294002 alone or in combination with TRAIL 
(100 ng/ml) for 24 h. 
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Mitochondrial activation is an essential event for efficient TRAIL-induced apoptosis in 
EOC cells (Cuello et al., 2004). We, therefore, examined the effect of TRAIL on 
mitochondrial outer membrane permeabilization and cytochrome c release in OVCAR3 and 
SKOV3ipl cells. Mitochondrial outer membrane permeabilization was assessed by the 
uptake of a lipophilic cationic dye where red fluorescence represents intact mitochondria 
membrane and green fluorescence represents apoptotic mitochondria. Treatment of 
OVCAR3 cells with TRAIL, increased the number of green labeled mitochondria (Figure 
5a) and consequently the percentage of apoptotic mitochondria as compared with 
SKOV3ipl cells (Figure 5b). Heavy membrane, enriched in mitochondria and cytosolic 
fractions, were isolated from OVCAR3 and SKOV3ipl cells, after treatment with TRAIL. 
Cytochrome c was detected in the cytosol of OVCAR3 cells as early as 2 h after TRAIL 
treatment whereas cytochrome c was not detected in SKOV3ipl even after 8 h of TRAIL 
treatment (Figure 5c). These results suggest the mitochondrial cell death pathway is 
inhibited in resistant cells. 
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Figure 5 Lack of mitochondrial activation in TRAIL-resistani cells, (a) OVCAR3 and 
SKOV3ipl cells were cultured for 24 h without TRAIL and the mitochondrial membrane 
integrity was assessed using MitoLight apoptotic detection kit staining. In treated cells, 
fresh culture medium containing TRAIL (100 ng/ml) was added for 5 h before subjected to 
MitoLight apoptotic detection kit staining. Only TRAIL-treated cells are shown. The red 
fluorescence (left panels) represents dimeric dye that has accumulated in the intact 
mitochondria membrane representing non-apoptotic cells. The green fluorescence (middle 
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panels) represents cytoplasmic pools of monomeric-lipophilic-cationic dye indicating the 
the lack of ability of mitochondria to concentrate the dye and consequently shows apoptotic 
cells. Right panels represent overlays of left and middle panels, (b) Percentage of apoptotic 
mitochondria in OVCAR3 and SKOV3ipl cells during TRAIL treatment, (c) OVCAR3 and 
SKOV3ipl cells were treated with TRAIL for different times and levels of cytochrome c in 
cytosolic (C) and membrane (M) fractions were determined by western blot. COX IV was 
used as a mitochondrial marker and loading control. 
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tBid is not detected in resistant cells 
TRAIL-induced Bid cleavage generates a truncated form of Bid (tBid) that promotes the 
insertion of Bax into the mitochondrial outer membrane. As shown in Figure 6a, TRAIL 
(100 ng/ml) treatment resulted in a reduction in full-length Bid and the appearance of tBid 
overtime in sensitive cells but not in resistant cells suggesting that Akt interfere with 
caspase-8-mediated Bid cleavage. To further support this observation, SKOV3ipl and 
COV2 cells were treated with TRAIL (100 ng/ml) in the presence or absence of LY294002 
(5 nM). When TRAIL was combined with LY294002, there was a reduction of full-length 
Bid, but we did not detect tBid presumably, because the levels of tBid are too low to be 
detected by immunoblot (Figure 6b). Overexpression of Aktl in CaOV3 cells prevented 
TRAIL-induced Bid cleavage (Figure 6c). These results suggest that Akt inhibits TRAIL 
induced activation of the mitochondrial cell death pathway by preventing the accumulation 
of tBid at levels sufficient to induce apoptosis. 
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Figure 6 Effect of Akt on Bid cleavage, (a) Immunoblot analysis for the assessment of Bid 
cleavage. Sensitive and resistant cells were treated with TRAIL (100 ng/ml) for various 
times and Bid cleavage was determined by the decrease of full-length Bid protein and the 
appearance of tBid on western blot using anti-Bid antibodies, (b) TRAIL-resistant 
SKOV3ipl and COV2 cells incubated with LY294002 (5 (iM) or left untreated for 1 h 
before adding TRAIL for 8 h. Cell lysates were analyzed by western blotting using the 
indicated antibodies, (c) CaOV3 cells expressing the empty vector (CaOV3-EV) or Aktl 
(CaOV3-Aktl) were treated with TRAIL for 8 h. Cell lysates were analyzed as described 
above. Tubulin was used to ensure equal loading. 
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Akt activation decreases Bid protein levels 
We compared levels of Bid protein in our TRAIL-sensitive and -resistant cell lines. The 
expression of Bid was lower in resistant cells, both, at the protein and transcriptional levels 
(Figures 7a and e). In contrast, the expression of Bcl-2, Bcl-XL, Mcl-1 and Bax did not 
correlate with TRAIL sensitivity as shown by immunoblot (Supplementary Figure SI 
online). We next examined Bid expression in CaOV3-EV and CaOV3-Aktl cells. The 
levels of Bid protein and mRNA were lower in Aktl overexpressing cells relative to 
CaOV3-vector cells (Figures 7b and f). When Akt activation was inhibited by a PI3K 
inhibitor, LY294002, in TRAIL-resistant cells, Bid expression was increased (Figure 7c). 
To further evaluate whether Akt inhibits Bid expression at the transcriptional level, we 
carried out Bid qRT-PCR at 2 and 6 h after exposure of CaOV3 cells to EOC ascites, 
which induce Akt activation within 30 min (Lane et al., 2010). As shown in Figure 7d, 
there was a decrease in Bid mRNA expression at 2 and 6 h. Taken together, these data 
suggest that Akt inhibits TRAIL-induced apoptosis by decreasing the expression of Bid. 
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Figure 7 Akt downregulates Bid expression, (a) Western blot analysis of Bid expression in 
TRAIL-sensitive and -resistant cells, (b) Bid expression in CaOV3 cells expressing the 
empty vector (CaOV3-EV) or Aktl (CaOV3-Aktl) assessed by western blot using anti-Bid 
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antibodies, (c) SKOV3ipl and COV2 were treated with LY294002 (5 jxM) or incubated in 
standard medium for 1 h and Bid expression was assessed by western blot. Tubulin was 
used to ensure equal loading, (d) CaOV3 cells were exposed to EOC COV2 ascites (10% 
v/v) to induce Akt phosphorylation at 2 and 6 h later, qRT-PCR analysis was performed for 
detecting Bid mRNA as described in Material and methods. Histogram represents mean-
fold change of Bid mRNA levels relative to cells which were not exposed to ascites. Bid 
expression and Akt phosphorylation were also assessed by western blot at 2 and 6 h to 
confirm that the decreased Bid at the protein level correlates with the phosphorylation of 
Akt. (e) Expression of Bid mRNA by qRT-PCR in our sensitive and resistant cell lines. 
Histogram represents of mean of normalized Bid mRNA and expressed relative to Bid 
mRNA levels in CaOV3 cells. (0 Histogram of mean of normalized Bid mRNA in CaOV3 
(vector) and CaOV3-Akt-l (wt) cells. Bid mRNA levels are expressed relative to CaOV3 
(vector) cells. 
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Depletion of Bid inhibits TRAIL-induced apoptosis 
We examined the effect of Bid depletion by RNA interference on TRAIL-induced 
apoptosis in TRAIL-sensitive OVCAR3 cells. Knockdown of Bid by siRNAs decreased the 
levels of Bid at 24 and 48 h, whereas, the control siRNA (siRNA Luc) did not affect Bid 
expression at 48 h (Figure 8a). Bid depletion completely inhibited TRAIL-induced cell 
death, as evident, by the same number of colonies found in long-term assays in the presence 
or absence of TRAIL (20 ng/ml) (Figure 8b). Apoptosis was also significantly reduced, 
(P<0.001) as shown by further limited oligosomal DNA fragmentation (Figure 8c) and 
lower percentage of hypodiploid cells, in the presence of Bid siRNA (Figure 8d). 
Consistent with these observations, we were unable to detect tBid by immunoblot in Bid 
siRNA-transfected cells whereas tBid was detected with the control siRNA (Figure 8e). We 
tried to perform similar experiments in CaOV3 cells, but were not able to obtain consistent 
downregulation of Bid in these cells. This was probably related to the fact that CaOV3 cells 
are relatively resistant to siRNA transfection, as we did not achieve efficient transfection 
with the control fluorescent siRNA (siRNA Luc), either. In all, our data suggest that Bid 
downregulation increased the resistance of OVCAR3 cells to TRAIL-induced apoptosis. 
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Figure 8 Bid depletion inhibits TRAIL-induced apoptosis. (a) Expression of Bid analyzed 
by western blot in OVCAR3 cells incubated with transfectant only (vehicle), control siRNA 
(siRNALuc) for 48 h or Bid siRNA and cell lysates were obtained at 24 and 48 h after 
transfection. Bid expression was assessed by western blot, (b) 48 h after transfection, 
TRAIL (20 ng/ml) was added for 24 h, after which the number of colonies was determined 
by staining with crystal violet after 14 days. OVCAR3 cells were left untreated or treated 
with TRAIL (20 ng/ml) 48 h after the transfection with siRNAs and apoptosis was 
measured by determining oligosomal DNA fragmentation 24 h after the addition of TRAIL 
(c) or by assessing the percentage of hypodiploid cells (d). Data shown are representative 
of three independent experiments. Values are the means ± s.e.m. *P<0.001. (e) Bid 
cleavage in OVCAR3 cells transfected with siRNA was determined by western blot. 
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Bid overexpression promotes TRAIL-induced apoptosis in resistant cells 
The requirement of Bid for TRAIL-induced apoptosis was confirmed by comparing the 
effects of stably expressing green fluorescent protein (GFP)-tagged Bid and GFP only in 
SKOV3ipl cells. TRAIL treatment induced the cleavage of GFP-tagged Bid as shown by 
immunoblot (Figure 9a). However, the cleavage of endogenous Bid could not be detected 
as previously shown (Figure 6). TRAIL treatment also induced greater apoptosis in 
SKOV3ipl cells overexpressing Bid compared with control cells (25.1±1.3 vs 12.7±0.8%, 
Figure 9b). Interestingly, the addition of LY294002 enhanced TRAIL-induced apoptosis in 
Bid-expressing SKOV3ipl cells (35±1.5 vs 25.1±1.3%) suggesting that the inhibition of 
Akt phosphorylation enhanced Bid cleavage or that it alleviate a downstream blockade. The 
basal level of apoptosis in Bid-expressing SKOV3ipl was unaffected by LY294002. 
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Figure 9 Overexpression of Bid in resistant cells increases TRAIL-induced apoptosis. 
TRAIL-resistant SKOV3ipl cells were stably transfected with GFP expression vector 
(GFP) or with GFP-tagged Bid vector (Bid-GFP). (a) After selection^, cells were analyzed 
for Bid expression and cleavage in the presence or absence of TRAIL (100 ng/ml) by 
immunoblot. (b) The percentage of apoptosis was measured as percentage of hypodiploid 
cells assessed by flow cytometry analysis during exposure to TRAIL (100 ng/ml) in the 
presence or absence of L Y294002 (5 nM) for 24 h. 
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TRAIL resistance is not affected by XIAP downregulation 
Bid and XIAP are substrates for caspase-3. In the presence of activated caspase-3, the full 
length 53 kDa XIAP protein is depleted and concomitant generation of a 30 kDa fragment 
occurs (Deveraux et al, 1999). XIAP, the most potent caspase inhibitor of the LAP family, 
has been shown to regulate drug- and death receptor-induced apoptosis in EOC cells 
(Asselin et al., 2001; Lane et al., 2006). XIAP binds to the active form of caspase-3, but not 
to pro-caspase-3, and promotes its proteasomal degradation (Griffith et al., 1998; Deveraux 
et al., 1999; Lane et al., 2006). As XIAP regulates caspase-3 activity, it may also affect Bid 
cleavage. We therefore compared the levels of XIAP expression in sensitive and resistant 
cells and in CaOV3-Akt-l (wt) cells. There was no difference in XIAP expression between 
the cell lines (Figures 10a and b). As expected, XIAP was cleaved in TRAIL-sensitive 
CaOV3 cells but not in SKOV3ipl cells (Figure 10c). To evaluate more specifically its 
contribution to TRAIL resistance, we downregulated XIAP expression with siRNA in 
SKOV3ipl cells (Figure lOd). This treatment efficiently abolished XIAP expression but did 
not substantially sensitize cells to TRAIL (Figure lOe). In addition, XIAP downregulation 
had no effect on the cleavage of Bid and TRAIL-induced caspase-3 activation remained 
unaffected (Figure lOf). These data suggest that XIAP do not significantly contribute to 
TRAIL resistance in SKOV3ipl cells and thus, support our concept that Akt interfere with 
Bid processing upstream of the mitochondria. 
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Figure 10 Effect of X-linked inhibitor of apoptosis (XIAP) depletion on TRAIL-induced 
apoptosis. (a) XIAP expression in sensitive and resistant cells determined by western blot, 
(b) XIAP expression in CaOV3-vector and CaOV3-Aktl wt cells evaluated by Western 
blot, (c) CaOV3 and SKOV3ipl cell were left untreated or were treated with TRAIL (100 
ng/ml) for 24 h. Cell lysates were analyzed by western blot for XIAP expression, (d) 
SKOV3ipl cells were transfected with control or XIAP siRNA. Cell lysates were obtained 
at 24, 48 and 72 h and XIAP expression was determined by western blot, (e) Transfected 
SKOV3ipl cells were left untreated or were treated with increasing concentration of 
TRAIL for 48 h. Cell viability was assessed by XTT assay after 48 h. Data shown are 
representative of four independent experiments. Values are the means ± s.e.m. (f) 
Transfected SKOV3ipl were left untreated or were treated with TRAIL (100 ng/ml) for 24 
h. Cell lysates were analyzed for evidence of Bid cleavage and caspase-3 activation by 
western blot. 
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DISCUSSION 
In this study, we show that the PI3K/Akt signaling pathway regulates TRAIL-induced 
apoptosis in EOC cells. Akt activation mediates TRAIL resistance by decreasing Bid 
expression and possibly by inhibiting its cleavage. We also showed that Akt activation 
correlates with decreased TRAIL sensitivity in primary cultures of ovarian carcinoma 
suggesting the importance of Akt activation in clinical setting. 
Because of the potential of TRAIL in antitumor treatment, considerable effort is 
being directed at understanding the determinant of TRAIL resistance in cancer cells. In 
addition, many tumor cells, and in particular EOC cells, appear, at least in vitro, resistant to 
TRAIL-induced apoptosis (Lane et al, 2004). Activation of the PI3K/Akt pathway is 
common in ovarian carcinoma (Bast et al, 2009). There have been several reports showing 
the role of Akt in EOC drug resistance (Page et al, 2000; Hu et al, 2002; Fraser et al, 
2003; Westfall and Skinner, 2005; Yang et al, 2006; Mabuchi et al, 2007). However, the 
role of Akt in promoting survival against death receptor-induced apoptosis in EOC cells has 
not been clearly defined. A few reports suggested a role for the PI3K/Akt pathway in 
mediating TRAIL resistance. In two of these studies, Akt activation mediated by EOC 
ascites or serum from ovarian cancer patients inhibited TRAIL-induced apoptosis (Kang et 
al, 2004; Lane et al, 2007). Conversely, the inhibition of Akt phosphorylation in TRAIL-
resistant SKOV3 cells enhanced TRAIL-induced apoptosis (Kim and Lee, 2005; Lane et 
al, 2008). Taken together, these studies suggested a role for Akt in the regulation of 
TRAIL-induced apoptosis. This study shows that overexpression of Aktl in TRAIL-
sensitive EOC cells, CaOV3 enhanced resistance to TRAIL whereas inhibition of PI3K or 
Akt decreased resistance to TRAIL-mediated cell death. Therefore, our data clearly 
established that the PI3K/Akt pathway has an important role in regulating TRAIL-induced 
apoptosis in EOC cells. Intrinsic resistance to TRAIL among ovarian cancer cells appears 
to be mediated, at least in part, by activation of this pathway. The clinical relevance of this 
observation was confirmed in primary cultures of tumor obtained from women suffering 
with advanced ovarian carcinoma. We established a statistical correlation between the 
levels of Akt phosphorylation and TRAIL-IC50 in the primary cultures. 
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The anti-apoptotic effect of Akt is believed to occur downstream of caspase-8 activation. 
Similarly, we found that Akt activation or its inhibition did not interfere with the 
recruitment and processing of pro-caspase-8 at the DISC. Activation of Akt inhibits 
apoptosis before mitochondrial cytochrome c release (Kandel and Hay, 1999). To promote 
release of cytochrome c, tBid translocates to the mitochondria where, in concert with pore-
forming Bax and Bak proteins, it activates the mitochondria (Luo et al, 1998). Although it 
is well established that Akt may function at the mitochondria by phosphorylating Bad 
which prevents its interaction with anti-apoptotic proteins Bcl-2/Bcl-XL, there have been a 
number of reports, suggesting that Akt acts upstream of the mitochondria, although the site 
of action of Akt in the apoptotic cascade was not certain. In one study, Akt activation did 
not prevent Bid cleavage but inhibited Bak oligomerization and Bax activation, which are 
critical events in tBid-induced apoptosis (Majewski et al., 2004). In another report, 
although the authors could not identify the precise mechanism by which tBid was unable to 
activate Bax or Bak in TRAIL-resistant colon cancer cells despite the fact the tBid 
effectively translocated to the mitochondria (Ndozangue-Touriguine et al., 2008). In this 
study, we showed that Akt activation prevents the accumulation of caspase-8-induced tBid 
in TRAIL-resistant EOC cells, as shown by the observation that Akt overexpression in 
TRAIL-sensitive EOC cells prevents the detection of tBid. The fact that overexpression of 
Bid in SKOV3ipl could induce apoptosis suggests that there was simply insufficient 
production of endogenous tBid after TRAIL treatment to directly activate Bak in these 
cells. The mechanism by which Akt interferes with the accumulation of tBid is not certain. 
Bid can be phosphorylated by casein kinase II leading to resistance to cleavage by caspase-
8 and resistance to TRAIL-induced apoptosis (Desagher et al., 2001; Izeradjene et al., 
2005). However, analyses of Bid phosphorylation by immunoblot in CaOV3 (vector) and 
CaOV3-Akt-l (wt), showed that, ectopic Aktl expression did not affect Bid 
phosphorylation (N. Goncharenko-Khaider, unpublished data) suggesting that Akt pathway 
does not block Bid cleavage by interfering with its phosphorylation. In addition, TRAIL-
induced apoptosis in resistant EOC cells was not affected by the chemical inhibition of 
casein kinase II with apigenin or with emodin (Lane D, unpublished data). It seems 
unlikely therefore that Akt affects Bid cleavage by interfering with Bid phosphorylation or 
by modulating the activity of casein kinase II. We cannot rule out the possibility that Akt 
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does not directly interfere with Bid cleavage, but instead regulates tBid degradation or acts 
downstream of Bid to antagonize tBid activity at the mitochondria. 
The anti-apoptotic protein Mcl-1, a member of Bcl-2 family, has emerged as an 
important regulator of TRAIL sensitivity (Kim et al, 2008). Mcl-1 can bind to pro-
apoptotic BH3-only proteins, such as Bim, Puma, and Bak, thereby inhibiting the activation 
of the mitochondria (Cheng et al., 2005). We have previously shown that ascites-induced 
Akt activation in CaOV3 cells does not affect the levels of pro-apoptotic proteins Bax and 
Bak and anti-apoptotic proteins Bcl-2 and Bcl-XL (Lane et al, 2007). Consistent with these 
results, we showed in this study that expression of Mcl-1, Bcl-2 and Bcl-XL did not 
correlate with resistance to TRAIL. 
Previous reports have suggested that in sensitive CaOV3 and HeLa cells, inhibition 
of TRAIL-induced apoptosis by Akt activation occurs by an upregulation of c-FLIP 
expression (Kang et al., 2004; Lane et al., 2007). Interestingly, we showed here that c-FLIP 
expression did not correlate with TRAIL sensitivity and c-FLIP expression was not affected 
by Akt inhibition in resistant cells. These data suggest that the mechanism by which Akt 
blocks the TRAIL signaling cascade may differ in sensitive vs resistant EOC cells. Akt 
activation in sensitive EOC cells may involve a dual resistance to TRAIL: a block at the 
DISC level through ascites-mediated upregulation of c-FLIPs (Lane et al, 2007) and a 
block at the Bid level because we showed that Aktl overexpression in sensitive CaOV3 
cells decreased Bid protein levels. In some context, XLAP has been shown to be a critical 
regulator of death receptor-induced apoptosis (Jost et al., 2009). Although the basal levels 
of XLAP were mostly comparable between sensitive and resistant cell lines, TRAIL 
treatment induced the cleavage of XLAP in sensitive cells, indicating that it is a 
consequence of cell death. However, the depletion of XIAP by siRNAs did not affect 
TRAIL-induced cell death, Bid levels and caspase-3 activation in SKOV3ipl cells, ruling 
out a prominent role for XIAP in mediating TRAIL resistance. 
In summary, we propose that binding of TRAIL to its cognate receptors induces 
caspase-8 activation at the DISC in both sensitive and resistant cells. In resistant cells, Akt 
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activation decreases Bid protein levels and possibly interferes with its cleavage. The level 
of tBid generated is therefore below a threshold that is insufficient to trigger Bid-mediated 
Bax or Bak activation. The lack of efficient mitochondrial activation prevents the 
mitochondrial feedback loop required to fully activate caspase-8 in the cytosol. However, 
the low level of Akt activation in sensitive cells is insufficient to decrease Bid levels or to 
prevent tBid accumulation. In these conditions the amount of tBid produced is sufficient to 
fully activate the formation of Bax/Bak complexes resulting in activation of the 
mitochondria. 
MATERIALS AND METHODS 
Ovarian cancer tumor samples and cell culture 
Tumor cells were isolated from EOC ascites fluids as described previously (Lane et al., 
2004). Informed consent was obtained from all participants for this institutional review 
board approved protocol. All samples were supplied by the Tumor Bank of the Reseau de 
Recherche en Cancer du Fond de Recherche en Sante du Quebec, Canada. All tumor cell 
samples were used at low passage (<10). The human EOC cell line CaOV3 and OVCAR3 
were obtained from the American Type Culture Collection (Manassas, VA, USA) and 
maintained in RPMI-1640 (Wisent, St-Bruno, QC, Canada) supplemented with 10% fetal 
bovine serum and insulin (10 mg/1). CaOV3 cells were cultured in Dulbecco's modified 
Eagle medium/F12 (Wisent) supplemented with 10% fetal bovine serum and 2mM 
glutamine. COV2 cells were derived from ascetic fluids obtained from a patient suffering 
with a primary stage III serous ovarian carcinoma and were maintained in Dulbecco's 
modified Eagle medium/F12 (Wisent) supplemented with 20% fetal bovine serum. The 
SKOV3ipl human EOC cell line was kindly provided by J. Price (MD Anderson Cancer 
Center, Houston, TX, USA) and maintained in Dulbecco's modified Eagle medium/F12 
supplemented with 10% fetal bovine serum (Wisent). 
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Reagents 
TRAIL was purchased from PeproTech (Rocky Hill, NJ, USA). HRP-conjugated anti-
mouse and -rabbit antibodies were purchased from Cell Signaling (Pickering, ON, Canada). 
Akt, caspase-3, caspase-9, COX IV, Bid and cytochrome c antibodies were also purchased 
from Cell Signaling. Antibodies for phospho-Akt (Ser-473) were obtained from Invitrogen 
(Biosource, Burlington, ON, Canada). Caspase-8 antibodies were obtained from R&D 
Systems (Minneapolis, MN, USA). Phenazine methosulfate and anti-tubulin antibody were 
obtained from Sigma. XTT reagents were from Invitrogen (Burlington, ON, Canada). 
LY294002 and Akt-specific inhibitor lL-6-hydroxymethyl-chiro-inositol 2(R)-2-0-methyl-
3-O-octadecylcarbonate were purchased from Sigma. Lipofectamine 2000 was purchased 
from Sigma (Oakville, ON, Canada). 
Retroviral preparation and transduction efficiency 
The pLPCXL retroviral vector construct encoding wild type (wt) Aktl was kindly provided 
by N. Rivard (University of Sherbrooke, Quebec, Canada). Retroviral particles were 
generated by transfecting 293T cells with pLPCXL-Aktl, pVPack-VSV-G and pVPack-GP 
(Invitrogen) and used to infect CaOV3 cells. Pools of productively infected cells obtained 
by selection with puromycin (0,4 mg/ml) for 10 days were used for further analysis. In the 
case of stable expression of Bid, SKOV3ipl cells were transfected with either pEGFPNl 
vector (Clontech, Mountain view, CA, USA) or pEGFPNl containing full-length Bid 
(cloned in EcoRl site), selected in G-418 (1 mg/ml) for 10 days, and then used as a pooled. 
Quantitative RT-PCR 
Total RNA was extracted from CaOV3 cells using TRIzol reagent according to the 
manufacturer's protocol and subjected to reverse transcription using Promega (Madison, 
WI, USA) reverse transcriptase enzyme. The integrity of the cDNA was assessed by 
SRBR-base quantitative PCR, done on four housekeeping genes: MRPL19, PUM1, 
GAPDH and actin. Each sample was normalized to housekeeping gene levels. Primer 
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sequences are available on request. Cycle conditions for all PCRs were as follows: an initial 
incubation of 2 min at 95 °C followed by 35 cycles at 94 °C for 30 s, 55 °C for 30 s, 72 °C 
for 60 s. The amplification was carried out by a 2 min incubation at 72 °C. PCR products 
quantification was performed as previously described (Klinck et ai, 2008). 
Cell viability assays 
Short-term cell viability in the presence or absence of TRAIL was determined by XTT 
assay. Briefly, cells were plated at 20 000 cells/well in 96-well plates in complete medium. 
The next day, cells (confluence 60-70%) were treated with human TRAIL and incubated 
for 48 h. At the termination of the experiment, the culture media was removed and a 
mixture of phosphate-buffered saline and fresh media (without phenol red) containing 
phenazine methosulfate and XTT was added and kept for 30 min at room temperature. The 
absorbance was determined using a microplate reader at 450nm (TecanSunrise, NC, USA). 
The percentage of cell survival was defined as the relative absorbance of untreated versus 
TRAIL-treated cells. For clonogenic survival assays, cells were plated in six-well tissue 
culture plates in standard medium. The next day, cells were treated with TRAIL (20-100 
ng/ml) for 24 h, followed by several washes with standard medium. Then, cells were 
incubated in standard medium for 14 days. Cells were fixed and stained with crystal violet. 
The number of colonies, consisting of >25 cells, in triplicate was counted. 
Apoptosis and caspase assays 
Caspase-3 and caspase-8 fluorogenic protease assays were performed according the 
manufacturer's protocol (R&D Systems). In brief, 3x 106 cells were lysed in 250 |il of cell 
lysis buffer, and total cell lysates were incubated with 50 |iM of DEVD-AFC (caspase-3) or 
IETD-AFC (caspase-8) substrate for 1 h at 37 °C. Caspase-3 and caspase-8 activities were 
measured on a Versa Fluor fluoremeter (BioRad, Hercules, CA, USA). Protein 
concentration of the lysates was measured with Bio-Rad protein assay kit according to the 
manufacturer's recommendations. The release of nucleosomal DNA into the cytoplasm as a 
measure of apoptosis was determined using the Cell Death Detection ELISA Kit (Roche, 
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Laval, Quebec, Canada) according to the manufacturer's instruction. The absorbance was 
determined using a microplate reader at 410 nm (TecanSunrise). Propidium iodide staining 
for DNA fragmentation was done by fixing cells and staining them with propidium iodide 
for DNA analysis content as previously described (Lane et al., 2006). A total of 10 000 
events were analyzed by flow cytometry and the percentage of hypodiploid cells was 
measured. 
Western blot analysis 
Cells were harvested and washed with ice-cold phosphate buffered saline. Whole cell 
extracts were prepared in lysing buffer (glycerol 10%, Triton X-100 1%, TRIS lOmM pH 
7.4, NaCl lOOmM, EGTA ImM, EDTA ImM, Na4P20720mM, NaF ImM, Na3V04 2mM 
and SDS 0.1%) containing protease inhibitors (O.lmM AEBSF, 5 ng/ml pepstatin, 0.5 
jig/ml leupeptin and 2 ng/ml aprotinin) and cytosolic proteins were separated by 12% 
SDS-PAGE gels. Lysates for phosphorylated proteins were prepared in the presence of 
phosphatase inhibitors (lOOmM sodium fluoride, 100 |iM sodium pyrophosphate and 250 
[iM sodium orthovanadate). Proteins were transferred to PVDF membranes (Roche) by 
electroblotting, and immunoblot analysis was performed as previously described (Lane et 
al, 2006). All primary antibodies were incubated overnight at 4 °C. Proteins were 
visualized by enhanced chemiluminescence (GE Healthcare, Baie d'Urfe, Quebec, 
Canada). 
Knockdown of Bid andXIAP 
The Fluorescein-labeled Luciferase GL2 duplex was used as a control, the Bid siRNA was 
obtained from Dharmacon Research (Lafayette, CO, USA) and XIAP siRNA (Signal 
Silence XLAP siRNA) were purchased from Cell Signaling. Cells (6><104) were seeded in 
six-well plates and allowed to adhere for 24 h. Cells (50% confluent) were transfected with 
a mixture containing Lipofectamine 2000 (Invitrogen Life Technologies, Burlington, ON, 
Canada), optiMEM (Invitrogen) and Bid siRNA (10 fiM) or XIAP siRNA (25 |aM). The 
siRNAs/oligofectamine mixture was then added to the media of six-well plates containing 
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cells. Cells were incubated for 4-6 h at 37 °C in a CO2 incubator and a medium containing 
fetal bovine serum was then added to it. After 48 h, TRAIL was added and cells were 
further incubated for another 48 h after which XTT assays were performed. For western 
blotting, the cells were lysed at 24 or 48 h post-transfection and total cell lysates were 
analyzed by immunoblot. 
Statistical analysis 
Statistical comparisons between two groups were performed using the Student's t-test and 
with ANOVA when comparing the data with more than two treatments groups. Statistical 
significance was indicated by P<0.05. The strength of the association between TRAIL IC50 
and Akt phosphorylation levels in primary tumor samples was measured using Pearson's 
correlation coefficient parametric approach. 
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Discussion and conclusions 
Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is a promising anticancer 
agent as it selectively kills tumor cells but spares normal cells. Resistance to TRAIL among 
ovarian cancer tumor cells could limit its therapeutic use. In the present study, we have 
investigated the mechanisms of intrinsic resistance to TRAIL among EOC cells. 
We have previously tested the effect of this agent on the panel of different EOC cell lines 
and primary samples and demonstrated that they have variable sensitivity to TRAIL 
(LANE et al, 2004). The cell lines were subdivided into TRAIL-sensitive (<20% cell 
viability) and TRAIL-resistant (80% cell viability) based on an XTT cell viability assay. 
For this study, we selected two TRAIL-sensitive cell lines (CaOV3 and OVCAR3) and two 
TRAIL-resistant cells (SKOV3ipl and COV2). We found that TRAIL-resistant cell lines 
have the highest basal activity of the Akt protein kinase. Because Akt is known to block 
apoptosis, we tested whether the inhibition of this pathway in TRAIL-resistant cell lines 
and Akt overexpression in TRAIL-sensitive cell lines would affect the sensitivity of these 
cells to TRAIL. We found that the treatment of TRAIL-resistant cells with PI3K inhibitor 
LY294002 or a specific Akt inhibitor sensitized these cells to TRAIL-induced apoptosis. 
Overexpression of Aktl in TRAIL-sensitive CaOV3 cells rendered them more resistant to 
TRAIL. These data suggested that Akt is a critical mediator of resistance to TRAIL in EOC 
cells. To further confirm the clinical relevance of these observations, we established a 
statistical correlation between the levels of Akt activation and the TRAIL-IC50 in the 
primary cultures of tumor cells obtained from women with advanced ovarian carcinoma 
and demonstrated that TRAIL-resistance correlates with higher levels of Akt activation. 
To identify which step of TRAIL-mediated apoptotic pathway is blocked in TRAIL-
resistant EOC cell lines, we investigated different steps of the apoptotic pathway activation 
in our TRAIL-resistant and -sensitive cell line models. Altered expression of the death 
receptors TRAIL-DR4 and -DR5 has been previously associated with resistance to TRAIL 
in some tumor cells. Several studies have demonstrated high expression of death receptors 
in TRAIL-sensitive tumor cells (FRANK et al., 1999; ZHANG and ZHANG, 2008). In 
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contrast, low or undetectable levels of death receptors DR4 have been found in resistant 
cancer cells (KIM et al, 2000). However, we found that expression of TRAIL death and 
decoy receptors at the cell surface of sensitive and resistant EOC cell lines was similar. In 
addition, endogenous expression of FADD and a protease-deflcient homolog c-FLIPs and 
C-FLIPL did not correlate with TRAIL sensitivy (LANE et al., 2004). Thus, in ovarian 
cancer cells, intrinsic TRAIL resistance does not appear to be mediated by alterations in 
death receptor expression. 
Further, we investigated the pro-caspase-8 activation at the DISC. Pro-caspase-8 typically 
exists as a monomer in cytosol, but upon DISC formation, it undergoes dimerization. The 
dimerization of two monomers of pro-caspase-8 (p55/p55) results in a conformational 
change, which exposes the active site of the caspase (MUZIO et al., 1998). Pro-caspase-8 
cleaves itself between pi8 and plO domains forming heterotetrameric complex (p43-
pl0/p43-pl0). This complex undergoes the second cleavage between p26 and pi 8 which 
frees the final product of caspase-8 (pl8-pl0/p-18-pl0) (CHANG et al, 2003). Cleaved 
caspase-8 then recognizes its downstream substrates (caspase-3 and pro-apoptotic protein 
Bid). We were able to detect the full length pro-caspase-8 (p55) and the processed caspase-
8 fragment (p43) at the DISC by immunoprecipitation in both TRAIL-sensitive and 
TRAIL-resistant cell lines suggesting that pro-caspase-8 is recruited and processed at the 
DICS in both cell line models. However, we were not able to detect the mature activated 
caspase-8 fragment (p 18/p 10) at the DISC. When we assessed caspase-8 activation by 
fluorometric assay, we detected caspase-8 activation in both TRAIL-sensitive and -
resistant cells, even though the amount of activated caspase-8 was lower in TRAIL-
resistant cells. Several studies have reported difficulty in detecting active caspase-8 at the 
DISC in type II cells (SCAFFIDI et al., 1998; SCAFFIDI et al., 1999; SCHUG et al, 
2010). Interestingly, it was recently demonstrated that activated caspase-8 is associated 
with mitochondrial membrane which is dependent on presence of the mature cardiolipin, 
where it forms macromolecular complex with Bid within which the cleavage of Bid occurs. 
This provides a means by which concentration of enzyme (caspase-8) and its substrate 
(Bid) occurs on the organelle where it is needed (mitochondria) (SCHUG et al., 2010). If 
indeed, upon its cleavage caspase-8 translocates and localizes at the mitochondria, it 
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explain why we did not detect activated caspase-8 at the DISC. Based on these results, we 
concluded that the DISC formation and the caspase-8 activation are not blocked in TRAIL-
resistant EOC cell lines. 
EOC cells are classified as type II cells, meaning that in these cells DISC assembly is 
slower and production of caspase-8 is lower. In this scenario, caspase-8 must engage the 
intrinsic (mitochondrial) pathway to amplify the death signal and execute apoptosis 
(OZOREN and EL-DEIRY, 2002). The transition from extrinsic pathway to the intrinsic 
pathway is achieved through caspase-8-mediated processing of Bid and the produced 
truncated Bid (tBid) shifts to a separate complex, containing Bax/Bak. Activated Bax and 
Bak undergo conformational changes, resulting in formation of giant pores in the outer 
mitochondrial membrane. As a result, cytochrome c is released in cytosol (WEI et al, 
2000). We have found that TRAIL-induced cytochrome c release was blocked in TRAIL-
resistant cells, but not in TRAIL-sensitive. Furthermore, we did not detect caspase-9 or 
caspase-3 activation in TRAIL-resistant cells whereas in TRAIL-sensitive cells these 
caspases were activated upon treatment with TRAIL. Thus, Akt blocks apoptosis in 
TRAIL-resistant EOC cell lines downstream of the DISC but upstream of the mitochondria 
(Figure 32). There have been several reports to suggest that Akt acts upstream of the 
mitochondria to regulate cell death by TRAIL, although the site of action of Akt in the cell 
death pathway was not well established (KANDASAMY and STRIVASTAVA, 2002; 
NESTEROV et al., 2001; GIBSON et al., 2002). The mitochondrial cell death pathway is 
regulated by the interaction between pro- and anti-apoptotic members of the Bcl-2 family. 
Consequently, we investigated the endogenous expression of pro-apoptotic protein Bid and 
demonstrated that Bid expression is significantly lower in TRAIL-resistant cell lines 
compare to sensitive. Importantly, we have shown that levels of the pro-apoptotic Bid 
protein were negatively regulated by Akt, since overexpression of Aktl in TRAIL-sensitive 
CaOV3 cells resulted in downregulation of Bid and inhibition of PI3K with LY294002 in 
TRAIL-resistant cells resulted in increased expression of Bid protein. In addition, we 
confirmed that Akt regulates Bid expression on transcriptional level, since Bid mRNA 
levels were decreased in CaOV3 cells overexpressing Aktl and TRAIL-resistant cells show 
lower levels of Bid mRNA compare to TRAIL-sensitive cells. We also showed that 
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overexpression of Bid-GFP in TRAIL-resistant cells not only induced cell death, but also 
resulted in cleavage of Bid-GFP. Interestingly, inhibition of PI3K with LY294002 in 
SKOV3ipl cells with forced Bid expression resulted in even more increased TRAIL-
induced apoptosis. In addition, knockdown of Bid by siRNA in TRAIL-sensitive cells 
inhibited TRAIL-induced Bid cleavage and decreased sensitivity of these cells to TRAIL. 
Taken together, these results demonstrated that Bid is a critical downstream target for Akt-
mediated TRAIL resistance. 
Apoptotic cascade activation in EOC calls 
TRAH.-sensitive TRML-rwIstamt 
Figure 32. Apoptotic cascade activation in EOC cells. Schematic representation of the 
apoptotic cascade in sensitive and resistant cells. Apoptotic molecules that are inserted into 
a blue rectangle were not associated with TRAIL resistance. Molecules inserted into a 
green oval have been found to be activated upon TRAIL treatment. Red X represents 
blockade in apoptotic pathway steps. 
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Since Bid is converted into its active form by caspase-8-mediated cleavage, we investigated 
Bid cleavage in our cell line models. We did not detect Bid cleavage in TRAIL-resistant 
EOC cells, whereas in TRAIL-sensitive cells we observed depletion of the full length Bid 
and appearance of tBid after 2h of exposure to TRAIL. In addition, we showed that 
overexpression of Aktl in TRAIL-sensitive CaOV3 cells resulted in the blockade of Bid 
cleavage and the inhibition of the PI3K with LY294002 in TRAIL-resistant cells resulted in 
the depletion of full length Bid, although we did not detect tBid on Western blot. One 
possible explanation for the lack of tBid detection is the fact that there could be a very low 
level of tBid produced in TRAIL-resistant cells that is not detectable by Western blot, 
considering the fact that the endogenous level of Bid is very low in these cells. It has been 
reported that tBid appears to be a target for ubiquitin/proteasome system (BREITSCHOPF 
et al., 2000). Another study demonstrated that upon Bid cleavage, the N-terminal fragment 
(tBid-N) is ubiquitinated and degraded, thus freeing the BH3 domain in the C-terminal 
fragment (tBid-C) and this unconventional ubiquitination and proteasome-dependent 
degradation of tBid-N is required to unleash pro-apoptotic activity of tBid-C (TAIT et al., 
2007). In addition, tBid was identified as a substrate of the ubiquitin ligase Itch, which can 
specifically interact with and ubiquitinate tBid, but not intact Bid. Itch can be positively 
regulated by the EGF pathway (AZAKIR et al., 2010). EGFR tyrosine kinase receptor 
exerts many of its biological activities through the activation of the PI3K/Akt pathway 
(GAN et al., 2010). This leads to the suggestion that removal of tBid by proteasomal 
degradation could result in disappearance of both Bid and tBid on our Western blot, 
although this remains to be confirmed. Thus, it would be interesting to investigate if the 
treatment of resistant cells with TRAIL in presence of proteasomal inhibitor would result in 
Bid cleavage and whether it would sensitize these cells to TRAIL. If the combined 
treatment with TRAIL and the proteasomal inhibitor in resistant cells increases the levels of 
tBid, then we could investigate if Akt is implicated in this effect by treating CaOV3 cells 
overexpressing Aktl with proteasomal inhibitor and TRAIL and see if Bid cleavage is 
restored in these conditions and if these cells become more sensitive to TRAIL. 
One would assume that since Akt is a protein kinase that can regulate activity of number of 
substrates by phosphorylation, it could directly phosphorylate Bid and possibly prevent its 
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cleavage. We assessed Bid phosphorylation in TRAIL-sensitive and -resistant cell lines, as 
well as in CaOV3 cells overexpressing Aktl and did not find any differences in 
phosphorylated Bid expression (data not shown). In one of the study which aimed to 
identify the kinase(s) responsible for Bid phosphorylation, it was demonstrated that casein 
kinase I and II can phosphorylate Bid, but not other protein kinase such as Akt, PKA, PKC 
and MAPK. When phosphorylated by casein kinase I and II, Bid was insensitive to 
caspase-8 cleavage in vitro (DESAGHER et al, 2001). However, we observed that TRAIL-
induced apoptosis in resistant EOC cells was not affected by chemical inhibition of casein 
kinase IF with apigenin or with emodin (data not shown). To investigate whether Akt can 
directly interact with Bid we performed immunoprecipitation of FLAG-tagged Akt with 
Bid. This experiment failed to demonstrate such an interaction. Although it remains 
unclear how the PI3K/Akt pathway inhibits Bid cleavage, our data suggests that it is not 
through direct interaction or through Bid phosphorylation. 
It has been documented that Akt may regulate a variety of apoptotic molecules in multiple 
ways (PARCELLIER et al., 2008). Therefore, it is possible that Bid is not the sole 
downstream target of Akt contributing to TRAIL resistance. It is well established that Akt 
may phosphorylate the pro-apoptotic protein Bad which prevents its interaction with anti-
apoptotic Bcl-2 and Bcl-XL (DATTA et al, 1997). We found that in CaOV3 cells 
overexpressing Aktl the level of phosphorylated Bad is indeed higher compare to control 
empty vector expressing cells (data not shown). Although it remains to be proven, Bad 
phosphorylation may contribute to TRAIL resistance. In addition, we investigated whether 
Akt can regulate expression of other Bcl-2 family members apart from Bid. We assessed 
expression of different pro- and anti-apoptotic proteins in our TRAIL-resistant and -
sensitive cell lines. We showed that expression of Bcl-2, Bcl-XL, Mcl-1, Bak, Bax, Bik, 
and Bad did not correlate with TRAIL-resistance. 
Previous reports have demonstrated that XIAP, the potent caspase inhibitor, is a critical 
regulator of TRAIL-induced apoptosis (VOLGER et al, 2007; JOST et al., 2009). XIAP 
can directly bind to the caspase-3 and send it to proteasomal degradation. Activated 
caspase-3, in its turn, can cleave Bid and XIAP (HORNLE et al, 2010; SLEE et al., 2000). 
100 
Since XIAP negatively regulates caspase-3 and caspase-3 can increase Bid cleavage, we 
investigated if XIAP could also be important for TRAIL resistance in EOC. However, we 
found no difference in XIAP expression between sensitive and resistant cell lines. As 
expected, we observed XIAP cleavage in TRAIL-sensitive cells (because caspase-3 is 
activated in these cells upon treatment with TRAIL), but not in TRAIL-resistant. In 
addition, downregulation of XIAP in TRAIL-resistant cell line SKOV3ipl had no effect on 
caspase-3 activation or Bid cleavage and it did not sensitize these cells to TRAIL-induced 
apoptosis (GONCHARENKO-KHAIDER et al., 2010). These data demonstrated that XIAP 
does not contribute significantly to TRAIL resistance. 
Conclusions 
In this study, we provide evidence that regulation of the pro-apoptotic protein Bid by 
PI3K/Akt pathway is important for TRAIL-resistance in EOC cells. We propose that 
TRAIL-sensitive EOC cell lines respond to TRAIL by assembly of the DISC and activation 
of the caspase-8. Caspase-8 cleaves the pro-apoptotic protein Bid and production of tBid 
allows MOMP and cytochrome c release, activation of caspase-9 and downstream effector 
caspases -3, -6, -7 leading to cell death (Figure 32). TRAIL-resistant EOC cells respond to 
TRAIL in the following manner: DISC is assembled and caspase-8 is activated but in the 
smaller amount compared to TRAIL-sensitive cells. Akt activation in TRAIL-resistant cells 
results in downregulation of Bid and this negative regulation occurs on transcriptional 
level. Akt also interferes with Bid cleavage by unknown indirect mechanisms. As a result, 
the level of produced tBid is very low in these TRAIL-resistant cells which is insufficient 
to trigger cytochrome c release and activate apoptotic cascade downstream of mitochondria 
(Figure 33). 
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Intrinsic pathway 
Cytochrome c V 
Apoptosls 
Figure 33. Proposed model of apoptotic cascade activation in TRAIL-resistant EOC 
cells. We propose that in TRAIL-resistant EOG cells binding of TRAIL to its receptors 
results in DISC assembly and caspase-8 activation but in the smaller amount compared to 
TRAIL-sensitive cells. Akt activation in TRAIL-resistant cells results in downregulation of 
pro-apoptotic protein Bid and this negative regulation occurs on transcriptional level. Akt 
also interferes with Bid cleavage by unknown indirect mechanisms. As a result, the level of 
produced tBid is very low in these TRAIL-resistant cells which is insufficient to trigger 
cytochrome c release and activate apoptotic cascade downstream of mitochondria. 
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Perspectives 
We speculate that Akt activation may be a potential biomarker to predict patient's response 
to TRAIL therapy and that the inhibition of the PBK/Akt pathway can become one of the 
strategies to overcome resistance to TRAIL therapy in ovarian cancer. We also propose that 
Bid protein could be targeted to reverse TRAIL resistance in epithelial ovarian cancer. 
Recently, Bid gene therapy has been tested against advanced lung cancer and has been 
shown to be safe and more effective with addition of cisplatin and dexamethasone 
(FUKAZAWA et al„ 2009). 
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